US6177121B1 - Composition and method for producing low cholesterol eggs - Google Patents
Composition and method for producing low cholesterol eggs Download PDFInfo
- Publication number
- US6177121B1 US6177121B1 US09/162,522 US16252298A US6177121B1 US 6177121 B1 US6177121 B1 US 6177121B1 US 16252298 A US16252298 A US 16252298A US 6177121 B1 US6177121 B1 US 6177121B1
- Authority
- US
- United States
- Prior art keywords
- cholesterol
- egg
- animal
- yolk
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims abstract description 130
- 235000012000 cholesterol Nutrition 0.000 title claims abstract description 62
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 235000013601 eggs Nutrition 0.000 title abstract description 62
- 238000004519 manufacturing process Methods 0.000 title description 12
- 241001465754 Metazoa Species 0.000 claims abstract description 59
- 235000013305 food Nutrition 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 35
- 230000017448 oviposition Effects 0.000 claims abstract description 11
- 210000002969 egg yolk Anatomy 0.000 claims description 44
- 239000002253 acid Substances 0.000 claims description 23
- 150000001875 compounds Chemical class 0.000 claims description 20
- 241000287828 Gallus gallus Species 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 8
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 6
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract description 37
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract description 25
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 43
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 43
- 229960005370 atorvastatin Drugs 0.000 description 42
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 33
- 229960002855 simvastatin Drugs 0.000 description 31
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 31
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 29
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 29
- 229960004844 lovastatin Drugs 0.000 description 28
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 28
- 239000003112 inhibitor Substances 0.000 description 26
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 26
- 238000011282 treatment Methods 0.000 description 23
- 230000000694 effects Effects 0.000 description 18
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 17
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 17
- 235000005911 diet Nutrition 0.000 description 17
- 210000004185 liver Anatomy 0.000 description 16
- 230000037213 diet Effects 0.000 description 13
- 241000271566 Aves Species 0.000 description 12
- 0 CC(=O)OC1CC(C)C~C2C1C(CCC1CC(O)CC(=O)O1)C(C)C~C~2.[Y] Chemical compound CC(=O)OC1CC(C)C~C2C1C(CCC1CC(O)CC(=O)O1)C(C)C~C~2.[Y] 0.000 description 12
- 229910052736 halogen Inorganic materials 0.000 description 12
- 125000005843 halogen group Chemical group 0.000 description 12
- 229910052739 hydrogen Inorganic materials 0.000 description 12
- 239000001257 hydrogen Substances 0.000 description 12
- 239000002245 particle Substances 0.000 description 12
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 10
- 101150102415 Apob gene Proteins 0.000 description 10
- -1 C1-4alkyl ester Chemical class 0.000 description 10
- 235000013330 chicken meat Nutrition 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 10
- 102000006010 Protein Disulfide-Isomerase Human genes 0.000 description 9
- 230000003228 microsomal effect Effects 0.000 description 9
- 108020003519 protein disulfide isomerase Proteins 0.000 description 9
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 230000002440 hepatic effect Effects 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 8
- 108010000912 Egg Proteins Proteins 0.000 description 7
- 102000002322 Egg Proteins Human genes 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 108020004463 18S ribosomal RNA Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 4
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 241000271567 Struthioniformes Species 0.000 description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 125000001246 bromo group Chemical group Br* 0.000 description 4
- 125000004093 cyano group Chemical group *C#N 0.000 description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 230000031787 nutrient reservoir activity Effects 0.000 description 4
- 125000004430 oxygen atom Chemical group O* 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 4
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 3
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 3
- 101710095342 Apolipoprotein B Proteins 0.000 description 3
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 3
- XWLXKKNPFMNSFA-UHFFFAOYSA-N CCC(C)(C)C(=O)OC1CC(C)C=C2C=CC(C)C(CCC(O)CC(O)CC(=O)O)C21 Chemical compound CCC(C)(C)C(=O)OC1CC(C)C=C2C=CC(C)C(CCC(O)CC(O)CC(=O)O)C21 XWLXKKNPFMNSFA-UHFFFAOYSA-N 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- 108090000943 Cholesterol 7-alpha-monooxygenases Proteins 0.000 description 3
- 102000004410 Cholesterol 7-alpha-monooxygenases Human genes 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 125000004423 acyloxy group Chemical group 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000000994 depressogenic effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000013345 egg yolk Nutrition 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000021050 feed intake Nutrition 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 150000002431 hydrogen Chemical group 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- 125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 102100027992 Casein kinase II subunit beta Human genes 0.000 description 2
- 101710158100 Casein kinase II subunit beta Proteins 0.000 description 2
- 241000271559 Dromaiidae Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- 102000002067 Protein Subunits Human genes 0.000 description 2
- 108010001267 Protein Subunits Proteins 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 241000270666 Testudines Species 0.000 description 2
- 101800000422 Vastatin Proteins 0.000 description 2
- 102400001190 Vastatin Human genes 0.000 description 2
- 108010090932 Vitellogenins Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000011544 gradient gel Substances 0.000 description 2
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 2
- 150000002367 halogens Chemical group 0.000 description 2
- 125000005059 halophenyl group Chemical group 0.000 description 2
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
- 108010052968 leupeptin Proteins 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 108010038232 microsomal triglyceride transfer protein Proteins 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 150000003233 pyrroles Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- VUAXHMVRKOTJKP-UHFFFAOYSA-N 2,2-dimethylbutyric acid Chemical compound CCC(C)(C)C(O)=O VUAXHMVRKOTJKP-UHFFFAOYSA-N 0.000 description 1
- WMHRYMDGHQIARA-UHFFFAOYSA-N 4-hydroxyoxan-2-one Chemical compound OC1CCOC(=O)C1 WMHRYMDGHQIARA-UHFFFAOYSA-N 0.000 description 1
- OUCSEDFVYPBLLF-KAYWLYCHSA-N 5-(4-fluorophenyl)-1-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-n,4-diphenyl-2-propan-2-ylpyrrole-3-carboxamide Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@H]2OC(=O)C[C@H](O)C2)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 OUCSEDFVYPBLLF-KAYWLYCHSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 101100148606 Caenorhabditis elegans pst-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101001072223 Gallus gallus Protein disulfide-isomerase Proteins 0.000 description 1
- 101000851131 Gallus gallus Vitellogenin-2 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101800000171 Lipovitellin I Proteins 0.000 description 1
- 101800001557 Lipovitellin-1 Proteins 0.000 description 1
- 101710112134 Major yolk protein Proteins 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical class [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000006027 corn-soybean meal Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 125000002704 decyl group Chemical class [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- HBYOLNPZXLHVQA-UHFFFAOYSA-J dicalcium dicarbonate Chemical compound [Ca+2].[Ca+2].[O-]C([O-])=O.[O-]C([O-])=O HBYOLNPZXLHVQA-UHFFFAOYSA-J 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000012248 genetic selection Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000003187 heptyl group Chemical class [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical class [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000021192 high fiber diet Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000002596 lactones Chemical group 0.000 description 1
- 210000005162 left hepatic lobe Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 235000015263 low fat diet Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229940099246 mevacor Drugs 0.000 description 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 125000001400 nonyl group Chemical class [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- JFNLZVQOOSMTJK-KNVOCYPGSA-N norbornene Chemical compound C1[C@@H]2CC[C@H]1C=C2 JFNLZVQOOSMTJK-KNVOCYPGSA-N 0.000 description 1
- 125000002347 octyl group Chemical class [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 125000001147 pentyl group Chemical class C(CCCC)* 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000001436 propyl group Chemical class [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019624 protein content Nutrition 0.000 description 1
- 238000011110 re-filtration Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 210000001534 vitelline membrane Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/105—Aliphatic or alicyclic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L15/00—Egg products; Preparation or treatment thereof
Definitions
- the present invention relates to an animal food composition effective in reducing the level of cholesterol in an egg and a method of producing low cholesterol eggs. More specifically, the invention relates to an animal food composition including an animal food and a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. The invention further relates to a method of producing low cholesterol eggs by administering an HMG-CoA reductase inhibitor to an egg-laying animal. The eggs so produced are also described.
- HMG-CoA 3-hydroxy-3-methylglutaryl coenzyme A
- Coronary heart disease is one of the leading causes of death in the United States.
- the relationship between elevated plasma cholesterol levels, especially plasma low density lipoprotein (LDL) cholesterol, and an increased risk of contracting coronary heart disease has been well established.
- LDL plasma low density lipoprotein
- a dietary cholesterol intake of less than 300 mg/day has been recommended for all Americans (National Institutes of Health Consensus Development Panel, 1985). Foodstuffs containing lowered levels of cholesterol are therefore desired.
- Each chicken egg contains about 215 mg cholesterol.
- Efforts at reducing the level of cholesterol in intact chicken eggs have included genetic selection, use of low fat and high fiber diets, administration of pharmacological agents and various egg selection methods. Many of these methods are tedious and others have not led to large decreases in egg cholesterol.
- An animal food composition effective in reducing the amount of cholesterol in an egg and a method of producing low cholesterol eggs are therefore needed. The present invention addresses these needs.
- the present invention relates to an animal food composition including an animal food and an HMG-CoA reductase inhibitor.
- the animal food composition is preferably an oviparous vertebrate food composition.
- the animal food composition is effective in reducing the amount of cholesterol in an egg.
- the HMG-CoA reductase inhibitor is preferably a compound having the following formula:
- R 1 is C 3-10 cycloalkyl; C 1-10 alkyl provided that the C 1-10 alkyl is not 1-methylpropyl if R 2 and R 3 are both methyl groups; C 1-10 CF 3 -substituted alkyl; phenyl; halophenyl; phenyl-C 1-3 alkyl; substituted phenyl-C 1-3 alkyl in which the substituent is halo, C 1-3 alkyl or C 1-3 alkoxy;
- R 2 is H, C 1-10 alkyl, or hydroxyl
- R 3 is H, C 1-10 alkyl
- the HMG-CoA reductase inhibitor is a compound of the following formula:
- X is —CH 2 —, —CH 2 CH 2 —, —CH 2 CH 2 CH 2 — or —CH 2 CH(CH 3 )—;
- R 1 is 1-naphthyl; 2-naphthyl; cyclohexyl; norbornenyl; 2-, 3-, or 4-pyridinyl; 2-, 3- or 4-pyridinyl-N-oxide; 2-, 3- or 4-(N—C 1-4 alkyl) pyridinium halide; phenyl; phenyl substituted with halogen, hydroxyl, trifluoromethyl, C 1-4 alkyl, C 1-4 alkoxy, C 2-8 alkanoyloxy; C 1-8 alkyl;
- R 2 and R 3 are independently hydrogen; cyano; trifluoromethyl; phenyl; C 1-4 alkyl; C 2-8 carboalkoxy; CH 2 OR 7 where R 7 is hydrogen, C 1-6 alkanoyl, —CONHR 8 where R 8 is a C 1-6 alkyl, phenyl or phenyl substituted with halogen or C 1-4 alkyl; halogen provided that if R 1 is 1-methylethyl, R 4 is 4-fluorophenyl and either of R 2 or R 3 is bromine, the other of R 2 or R 3 is not bromine; or
- R 2 or R 3 is —CONR 5 R 6 where R 5 and R 6 are independently hydrogen; C 1-6 alkyl; 2-, 3- or 4-pyridinyl; phenyl; phenyl substituted with halogen, cyano, trifluoromethyl or C 3-8 -carboalkoxy; and the other of R 2 or R 3 is hydrogen; C 1-6 alkyl; cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl; phenyl; phenyl substituted with halogen, hydroxyl, trifluoromethyl, C 1-4 alkyl, C 1-4 alkoxy, or C 2-8 alkanoyloxy; and
- R 4 is C 1-6 alkyl, cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl; trifluoromethyl; phenyl; or phenyl substituted with halogen;
- a method of lowering the amount of cholesterol in an egg includes administering to an egg-laying animal an effective amount of the above-described compounds.
- the method is preferably carried out with chickens but may be carried out with any oviparous vertebrate, including turkey, geese, quail, rattites (including ostriches, emus and rheas) turtles and fish.
- an egg produced by the above-method is also described.
- FIG. 3 represents a northern blot analysis of hepatic microsomal triglyceride transport protein (MTP) large subunit, protein disulfide isomerase (PDI), HMG-CoA reductase (HMGR), and apolipoprotein B (apoB) mRNA in control (numbers 1-10) and statin-treated (numbers 11-40) laying hens.
- MTP hepatic microsomal triglyceride transport protein
- PDI protein disulfide isomerase
- HMGR HMG-CoA reductase
- apoB apolipoprotein B
- Approximate sizes of the mRNAs were: MTP, 1.4 kb; PDI, 2.7 kb; HMGR, 4.0 kb; apoB, 14 kb; and 18S, 1.8 kb. Because of the large size of the apoB mRNA, total RNA was separated on an additional agarose gel (0.8%), transferred, and probed, whereas MTP, PDI, and HMGR signals were visualized by sequential probing and stripping of the same membrane replica of a 1% agarose gel.
- FIG. 4 is a graph showing the comparative effects of atorvastatin (A), lovastatin (L), and simvastatin (S) on hepatic microsomal triglyceride transport protein (MTP) large subunit, protein disulfide isomerase (PDI), HMG-CoA reductase (HMGR), and apolipoprotein B (apoB) mRNA.
- MTP hepatic microsomal triglyceride transport protein
- PDI protein disulfide isomerase
- HMGR HMG-CoA reductase
- apoB apolipoprotein B
- FIG. 7 depicts a sodium dodecyl sulfate (SDS) polyacrylamide gel (4.5-18% gradient gel) with whole yolk extracts from control hens and HMG-CoA reductase inhibitor-treated hens.
- Lane 1 contained protein standards (molecular weights [kDa] are indicated); lanes 2 and 9 contained yolk extracts from control hens; lanes 3 to 8 contained yolk extracts from hens fed 0.03% atorvastatin, 0.06% atorvastatin, 0.03% lovastatin, 0.06% lovastatin, 0.03% simvastatin, and 0.06% simvastatin, respectively.
- Lane 10 contained yolk VLDL. Each lane contained 12 ⁇ g of protein.
- the gel was stained with Coomassie Brilliant Blue R-250 containing 20 mM AlCl 3 in order to visualize the phosvitin bands ( ⁇ 37-45 kDa).
- the position of the largest VLDL apolipoprotein B fragment is indicated by an asterisk, while the position of lipovitellin I, the largest major vitellogenin (VTG) fragment, is indicated by a plus sign.
- the present invention relates to an animal food composition effective in reducing the cholesterol content of an egg, a method of reducing the cholesterol content of an egg and an egg having a decreased amount of cholesterol produced by the method.
- the compounds used in the method are inhibitors of the rate-limiting enzyme in cholesterol biosynthesis, HMG-CoA reductase, and are preferably members of the class of drugs known as statins.
- the inhibitors are advantageously administered to poultry, especially chickens.
- an animal food composition effective in reducing the amount of cholesterol in an egg includes an animal food and a compound with a substituted polyhydronapthalene nucleus having the following formula (I):
- R 1 is C 3-10 cycloalkyl; C 1-10 alkyl provided that the C 1-10 alkyl is not 1-methylpropyl if R 2 and R 3 are both methyl groups; C 1-10 CF 3 -substituted alkyl; phenyl, halophenyl; phenyl-C 1-3 alkyl; substituted phenyl-C 1-3 alkyl in which the substituent is halo, C 1-3 alkyl or C 1-3 alkoxy;
- R 2 is H, C 1-10 alkyl, or hydroxyl
- R 3 is H, C 1-10 alkyl
- R 2 is further preferably a methyl group or a hydroxyl group and R 1 is further preferably 1,1-dimethylpropyl.
- R 1 may be 1-methylpropyl unless R 2 and R 3 are both methyl groups.
- R 3 is advantageously a methyl group.
- the compound is further preferably a 2,2-dimethylbutyric acid 8-ester with (4R,6R)-6-[2-[1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl]ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one (simvastatin).
- Other preferred embodiments are delineated in U.S. Pat. Nos. 3,983,140; 4,049,495; 4,231,938; 4,346,227; 4,432,996; and 4,444,784.
- the compounds, including ML-236B (wherein R 1 is 1-methylpropyl, R 2 is hydrogen and R 3 is a methyl group) and its derivatives, may be isolated and purified from fungi as known in the art and as shown in U.S. Pat. Nos. 3,983,140; 4,049,495; 4,231,938; 4,346,227; and 4,432,996 which are hereby incorporated by reference in their entirety.
- the compounds shown above may also be synthesized by methods known in the art and as described in U.S. Pat. No. 4,444,784 and U.S. patent application Ser. No. 118,050 filed Feb. 4, 1980 which are also hereby incorporated by reference in their entirety.
- alkyl means a saturated or unsaturated aliphatic hydrocarbon which may be either straight chain or branched and includes methyl, ethyl and structural isomers of propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl.
- Alkoxy means an alkyl group as defined above attached to an oxygen atom.
- Carboalkoxy means an alkoxy group as defined above attached through the oxygen atom to a carbonyl group.
- Norbornenyl means a group derived by the removal of a hydrogen atom (other than at a bridgehead carbon atom) from bicyclo[2.2.1]hept-2-ene.
- Alkanoyloxy means an alkyl group attached to a carbonyl group which is attached to an oxygen atom.
- the animal food composition includes compounds I and II above having the following configuration (III):
- R 1 , R 2 and R 3 are as defined for compound I above; or the corresponding dihydroxy acid having the following configuration (IV):
- the animal food composition includes a compound having a substituted pyrrole of the following formula (V):
- X is —CH 2 —, —CH 2 CH 2 —, —CH 2 CH 2 CH 2 — or —CH 2 CH(CH 3 )—;
- R 1 is 1-naphthyl; 2-naphthyl; cyclohexyl; norbornenyl; 2-, 3-, or 4-pyridinyl; 2-, 3- or 4-pyridinyl-N-oxide; 2-, 3- or 4-(N—C 1-4 alkyl) pyridinium halide; phenyl; phenyl substituted with halogen, hydroxyl, trifluoromethyl, C 1-4 alkyl, C 1-4 alkoxy, C 2-8 alkanoyloxy; C 1-8 alkyl;
- R 2 and R 3 are independently hydrogen; cyano; trifluoromethyl; phenyl; C 1-4 alkyl; C 2-8 carboalkoxy; CH 2 OR 7 where R 7 is hydrogen; C 1-6 alkanoyl, —CONHR 8 where R 8 is a C 1-6 alkyl, phenyl or phenyl substituted with halogen or C 1-4 alkyl; halogen provided that if R 1 is 1-methylethyl, R 4 is 4-fluorophenyl and either of R 2 or R 3 is bromine, the other of R 2 or R 3 is not bromine; or
- R 2 and R 3 is —CONR 5 R 6 where R 5 and R 6 are independently hydrogen; C 1-6 alkyl; 2-, 3- or 4-pyridinyl; phenyl; phenyl substituted with halogen, cyano, trifluoromethyl or C 3-8 carboalkoxy; and the other of R 2 or R 3 is hydrogen; C 1-6 alkyl; cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl; phenyl; or phenyl substituted with halogen, hydroxyl, trifluoromethyl, C 1-4 alkyl, C 1-4 alkoxy, or C 2-8 alkanoyloxy; and
- R 4 is C 1-6 alkyl, cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl; trifluoromethyl; pheny; or phenyl substituted with halogen;
- X is preferably a methylene (—CH 2 CH 2 —) group.
- R 1 is preferably a C 1-3 alkyl group and is further preferably 1-methylethyl.
- R 2 is preferably —CONR 5 R 6 , R 5 is preferably hydrogen and R 6 is a preferably a phenyl group.
- R 4 is advantageously a substituted phenyl, preferably 4-fluorophenyl.
- R 3 is preferably a phenyl group.
- R 2 and R 3 may also both be methylene groups joined together in a ring through 3 or 4 methylene groups or through an oxygen atom.
- R 2 and R 3 may also both be carbonyl groups and may be joined together in a ring through a nitrogen atom.
- the nitrogen atom is further attached to a hydrogen, a C 1-4 alkyl, or a benzyl group.
- R 2 is —COR 9
- R 3 is —COR 10 and R 9 and R 10 are attached to each other to form a ring.
- R 9 and R 10 are each a nitrogen atom and each nitrogen atom is independently attached to hydrogen, C 1-4 alkyl, or a benzyl group.
- Other preferred embodiments are delineated in U.S. Pat. Nos. 4,647,576; 4,681,893 and 5,273,995.
- Compound V is further preferably ( ⁇ R, ⁇ R)-2-(p-fluorophenyl)- ⁇ , ⁇ -dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoic acid) (atorvastatin).
- the lactone form of atorvastatin is (2R-trans)-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide.
- compounds V and VI preferably have the following configuration (VII):
- R 1 , R 2 , R 3 and R 4 are as defined for compounds V and VI;
- R 1 , R 2 , R 3 and R 4 are as defined for compounds V and VI;
- substituted pyrroles may be synthesized by methods known in the art as described in U.S. Pat. Nos. 4,647,576,; 4,681,893; 5,273,995 and as similarly described in Roth, B. D. et al., J. Med. Chem. 34:357-366 (1991), all hereby incorporated by reference in their entirety.
- the present invention can use any compatible animal food, including dry animal food.
- the composition of the animal food is not a critical part of the invention, but will depend on the egg-laying animal it will be administered to. Suitable animal foods are readily available commercially.
- the animal food is preferably an oviparous vertebrate animal food. If the egg-laying animal is a chicken, the composition may typically include, for example, corn and soybean meal (about 66.15% and about 21.29% by weight, respectively).
- the chicken food may also contain, on a weight percent basis, about 1.75% alfalfa meal, about 1.50% dicalcium carbonate, about 5.38% calcium carbonate, about 2.74% oyster shell, about 0.45% sodium chloride, about 0.25% vitamins and trace minerals, about 1% soybean oil, about 0.06% of a methionine hydroxy analogue (calcium), about 0.1% of an antioxidant and about 0.05% of a mold inhibitor.
- the vitamin and trace mineral mix may be any such mix as known in the art, such as the mix of DI-Egg (Dawe's Laboratories, Chicago Ill.). Any antioxidant known in the art may be used, such as that sold under the name Dry Polyanox from Agrimerica, Inc., Northbrook, Ill.
- the mold inhibitor includes typical inhibitors known in the art, such as those purchased from Agrimerica under the name of Dry Mold-Chek Plus 5762. It will be recognized that certain components in the diet may be removed and other components added, depending on the situation. Moreover, it will be recognized that the relative proportions of the compounds in the animal food mixture may be increased or decreased depending on the situation. Animal food compositions for other oviparous vertebrates are well known in the art.
- the method includes administering to an egg-laying animal an amount of a cholesterol-reducing component effective in reducing the amount of cholesterol in an egg.
- the cholesterol-reducing component is preferably an HMG-CoA reductase inhibitor.
- the HMG-CoA reductase inhibitor is typically added to the food of the animal in a quantity that will reduce the level of cholesterol in an egg.
- the inhibitor is typically included in the food by methods known in the art, including adding the inhibitor directly to the food or to a carrier with subsequent addition of the carrier/inhibitor mixture to the food.
- the inhibitor may be mixed with a vegetable oil and the vegetable oil/inhibitor mixture may be mixed into the food.
- the inhibitor may be mixed with an organic solvent, the inhibitor/solvent mixture may be mixed with the food and the organic solvent is then allowed to volatilize.
- the inhibitor will preferably reduce the amount of cholesterol in the yolk of an egg by at least about 5%, 10%, 15%, 20%, 25% and 30% per gram of yolk.
- the amount of inhibitor will most preferably reduce the amount of cholesterol in the yolk of an egg by at least about 35% per gram of yolk.
- the amount of inhibitor required to reduce the cholesterol in an egg will vary depending on factors including the potency of the inhibitor, egg size and the rate of biological degradation of the inhibitor.
- the quantity of inhibitor typically administered is in the range of about 5 mg/animal/day to about 265 mg/animal/day, preferably about 15 mg/animal/day to about 150 mg/animal/day, further preferably about 25 mg/animal/day to about 100 mg/animal/day and most preferably about 30 mg/animal/day to about 60 mg/animal/day.
- the dosage is based on the animal eating about 100 g of food/day.
- the food must be supplemented with about 0.03% by weight of the inhibitor.
- the inhibitor may be administered over the entire laying cycle (e.g., about 20 to about 70 weeks of age) and subsequent cycles.
- initial decreases in egg cholesterol may be seen after about 7 to about 42 days after the dose regimen has begun.
- larger daily doses may be required if it is desired to obtain cholesterol reduction in a shorter period of time. It must be recognized that, if the doses are large enough to completely inhibit cholesterol synthesis, steroid hormone production could be impaired which would result in the failure of the animal to lay eggs.
- the method is particularly advantageous in lowering the level of cholesterol in chicken eggs.
- the method of reducing the level of cholesterol may be applied to any oviparous vertebrate, including geese, turkey, quail, rattites (including ostriches, emus and rheas), turtles and fish.
- single degree of freedom linear contrasts were also performed as described in the above Steel and Torrie reference. Individual treatment differences were tested by Duncan multiple range test as described in the above Steel and Torrie reference. Differences at P ⁇ 0.05 were considered significant. Moreover, the hens initial body weights in the Examples that follow ranged from 1,556 g to 1,646 g (P>0.05) and, during the course of the 5-week study, the birds gained between 67 g and 137 g (data not shown). Feed intakes did not differ (P>0.05) among treatments and ranged from 99-106 g/bird/day (data not shown).
- HMG-CoA reductase inhibitors were fed at dietary levels of 0.03% or 0.06%, all treated hens consumed approximately 30 or 60 mg of compound/bird/day, respectively. On a body weight basis, this equated to daily doses of approximately 19 or 38 mg HMG-CoA reductase inhibitor/kg body weight.
- Atorvastatin was provided by Parke-Davis. The drug was synthesized as described in Roth, et al., J. Med. Chem., 34:357-366, 1991. Lovastatin (Merck, Sharp & Dohme) was prepared by extracting formulated capsules of Mevacor as described in Bocan, Biochim. Biophys. Acta, 1123:133-144, 1992, whereas simvastatin was provided by Merck, Sharp & Dohme.
- Lovastatin was the least efficacious of the three statins, as evidenced by maximal yolk cholesterol reductions of 7% on a mg/g basis (10.8 vs. 11.6, respectively) and 7% on a per yolk basis (186.9 vs. 201.5, respectively) in hens fed the higher dose.
- Example 2 Hens were treated as described in Example 1. Egg yolk was weighed as outlined in Example 2. The results are shown in Table 2.
- Hen-day egg production was calculated as (100 ⁇ number of eggs laid)/(number of hens ⁇ days). For the 10 days immediately preceding the commencement of the study, the average hen-day egg production, egg weights, and yolk weights for each treatment group were 86%, 65.0 g, and 17.5 g, respectively. Number of eggs or yolks for each overall mean (weeks 1-5) are in parentheses. a-d Within a column, means with different superscripts are significantly different (P ⁇ 0.05).
- Plasma VLDL were isolated as described in Elkin, R G., and Schneider, W. J., Poult. Sci. 73:1127-1136 (1994), and the lipid composition of plasma VLDL was determined based on the extraction procedure of Slayback et al., Anal. Biochem., 83:372-384 (1977), and the HPLC method of Homan R., and Anderson, M. K., J. Chromatogr. B., 708:21-26, (1998).
- a carbon-coated formvar grid was initially floated on a drop of each VLDL sample. If the sample was too concentrated, it was diluted (10-or 100-fold) in a buffer containing 0.15 M NaCl, 0.2 mM EDTA, 1 mM PMSF, and 5 ⁇ M leupeptin. After the grid floated on the drop for 5-10 minutes, the grid was removed and excess fluid drawn off with a piece of filter paper. The grid was then touched to 1% aqueous uranyl acetate and the excess stain removed with filter paper. Samples were examined in a JEOL JEM-100CX transmission electron microscope (JEOL, Tokyo, Japan) operating at 80 kV.
- Particle composition data are from single analyses of one plasma VLDL sample per hen per diet.
- EC esterified cholesterol
- UC unesterified cholesterol
- TG triglyceride
- PE phosphatidylethanolamine
- PC phosphatidylcholine
- SM sphingomyelin.
- VLDL particle diameters were reduced (P ⁇ 0.05) only in hens fed 0.06% atorvastatin, and the particles were richer in protein and contained 79% and 36% less esterified- and unesterified-cholesterol, respectively, than controls.
- atorvastatin as well as both doses of lovastatin and simvastatin, also significantly lowered VLDL-esterified cholesterol levels, they did not affect (P>0.05) the relative proportion of unesterified cholesterol, which was the major form of this sterol present in the VLDL particles.
- Example 2 The birds were treated and samples were prepared as described in Example 1.
- One gram of each liver sample was homogenized with 12 ml of chloroform-methanol 2:1 (by vol.) and filtered directly into a 50 ml volumetric flask using a glass microfiber filter.
- the liver filtrates were diluted to a final volume of 50 ml with chloroform-methanol 2:1 (by vol.) and analyzed for cholesterol content by the method of Rudel and Morris described in Example 2. The results are shown in Table 4 below.
- Table 4 also shows that, although all of the HMGR inhibitor-treated groups had significantly lower cholesterol contents on a per g of tissue basis, liver total cholesterol values were unaffected (P>0.05) by dietary treatment when expressed on a whole organ basis.
- liver microsomes were isolated by ultracentrifugation as described in Junker, L. H. and Story, J. A., Lipids 20:712-718, 1985 and stored in liquid nitrogen until use.
- Microsomal HMG-CoA reductase activity was determined by measuring the conversion of 14 C-HMG-CoA to 14 C-mevalonate as described in Shapiro, D. J., et al., Biochim. Biophys. Acta 370:369-377 (1974), while microsomal cholesterol 7 ⁇ -hydroxylase activity was determined by measuring the incorporation of phospholipid liposome-solubilized 14 C-cholesterol into 14 C-7 ⁇ -hydroxycholesterol as described in Junker, L. H. and Story, J. A., Lipids 20:712-718 (1985).
- FIG. 1 shows that microsomal HMG-CoA reductase activities were significantly elevated 2- to 3-fold in the livers of all statin-fed animals vs. controls, while FIG. 2 shows that none of the HMG-CoA reductase inhibitors had a significant effect on hepatic microsomal cholesterol 7 ⁇ -hydroxylase activity.
- the hens were treated and samples were prepared as described in Example 1.
- Northern Blotting was performed to determine the effects of the HMG-CoA reductase inhibitors on the abundance of liver HMG-CoA mRNA as well as that of three other genes whose products play a key role in the hepatic synthesis of VLDL: apoB and the two components of the heterodimeric microsomal triglyceride transfer protein (MTP; ie., the large subunit and protein disulfide isomerase).
- MTP microsomal triglyceride transfer protein
- RNA extracted Approximately 1 g of liver from each hen was homogenized in guanidinium thiocyanate solution (4M guanidinium thiocyanate, 25 mM sodium citrate [pH 7.4], 0.5% sarcosyl, and 0.1M ⁇ -mercaptoethanol) and total RNA extracted according as described in Chomczynski, P., and Sacchi, N., Anal. Biochem. 162:156-159 (1987).
- guanidinium thiocyanate solution 4M guanidinium thiocyanate, 25 mM sodium citrate [pH 7.4], 0.5% sarcosyl, and 0.1M ⁇ -mercaptoethanol
- RNA (20 ⁇ g) was separated by electrophoresis on either a 0.8% or a 1% agarose gel according to Sambrook et al., Molecular Cloning, 2 nd ed., Cold Spring Harbor Laboratory Press, Plainview, N.Y., 1.12 (1989) as modified by Tsang et al., Biotechniques 14:380-381 (1993).
- the integrity of the 28S and 18S rRNA was verified after staining with ethidium bromide and the gel was washed twice for 15 minutes in 1M ammonium acetate and transferred to a Genescreen membrane by capillary action.
- RNA cross-linking, pre-hybridization, hybridization, and wash steps were performed as described by Donkin et al., J. Molec. Endocrinol. 16:151-158 (1996).
- the abundance of target RNA was visualized on Kodak X-Omat AR film (Eastman Kodak Co., Rochester, N.Y.). Membranes were reprobed following stripping in 0.1 ⁇ SSC and 1% SDS at 100° C. for 1 hour. Variations in loading and transfer of RNA were determnined using cDNA for rat 18S rRNA as described in Donkin et al., J. Molec. Endocrinol. 16:151-158 (1996).
- the plasmid ChMTP a full-length cDNA clone for the large subunit of chicken microsomal triglyceride transfer protein (MTP) was a gift from Dr. David A. Gordon (Department of Metabolic Diseases, Bristol-Myers Squibb, Princeton, N.J.).
- the 2.9 kb fragment cDNA was cloned into the BamHI/BamHi site of plasmid pcDNA-3.0 (Invitrogen, Carlsbad, Calif.).
- the plasmid CB13-1 a 960 bp fragment encoding the N-terminal part of chicken protein disulfide isomerase (PDI) described in Parkkonen et al., Biochem J.
- the plasmid pDF 8 containing a 1.1 kb BaniHI-EcoRI fragment corresponding to the central region of the rat 18S rRNA gene was kindly provided by Dr. Richard Torzynski (Cytoclonal Pharmaceuticals, Dallas, Tex.). This clone reacts with 18S rRNA from a number of species, including chicken, cow, and pig (S. S. Donkin, unpublished).
- Insert cDNA was excised from the plasmids by restriction enzyme digestion, separated by electrophoresis through low melting temperature agarose, and purified by lithium chloride precipitation as describe in Favre, D. Biotechniques 13:24 (1992).
- DNA probes were labeled with 32 P-labeled dCTP using the Ready-to-GoTM random oligonucleotide priming kit (Pharmacia Biotech, Inc., Piscataway, N.J.) to a specific activity of approximately 10 9 cpm/ ⁇ g DNA.
- Plasma samples obtained as described in Example 1 were analyzed for total cholesterol content according to the method of Rudel and Morris described in Example 2. Free glycerol-corrected total plasma triglyceride concentrations were determined using a commercial kit (Triglycerides-GB, Boehringer Mannheim Diagnostics, Indianapolis, Ind.).
- FIG. 5 shows that plasma total cholesterol concentrations were lowered (P ⁇ 0.05) by both the 0.03% and 0.06% doses of atorvastatin ( ⁇ 56%, ⁇ 63%) and simvastatin ( ⁇ 36%, ⁇ 45%), while plasma triglycerides, as seen in FIG. 6 were depressed (P ⁇ 0.05) only with atorvastatin ( ⁇ 57%, ⁇ 71%). Lovastatin did not significantly affect any of the plasma lipid variables.
- FIG. 7 Representative yolk protein profiles of eggs from the statin-fed birds are shown in FIG. 7 (lanes 3-8) and appeared to be very similar to those of control hens (FIG. 7, lanes 2 and 9). This suggested that the proportion of VLDL relative to VTG, the other major yolk protein precursor, was not selectively reduced by HMGR inhibitor treatment of the hens.
Abstract
An animal food composition effective in reducing the amount of cholesterol in an egg including an animal food and an HMG-CoA reductase inhibitor, preferably a statin, is described. A method of reducing the amount of cholesterol in an egg by administering to an egg-laying animal an amount of a cholesterol-reducing component effective in reducing the amount of cholesterol in said egg and the eggs produced are also described.
Description
This application claims the benefits of the earlier filed U.S. Provisional Application Serial No. 60/060286, filed Sep. 29, 1997.
The present invention relates to an animal food composition effective in reducing the level of cholesterol in an egg and a method of producing low cholesterol eggs. More specifically, the invention relates to an animal food composition including an animal food and a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. The invention further relates to a method of producing low cholesterol eggs by administering an HMG-CoA reductase inhibitor to an egg-laying animal. The eggs so produced are also described.
Coronary heart disease is one of the leading causes of death in the United States. The relationship between elevated plasma cholesterol levels, especially plasma low density lipoprotein (LDL) cholesterol, and an increased risk of contracting coronary heart disease has been well established. In light of this relationship, a dietary cholesterol intake of less than 300 mg/day has been recommended for all Americans (National Institutes of Health Consensus Development Panel, 1985). Foodstuffs containing lowered levels of cholesterol are therefore desired.
Each chicken egg contains about 215 mg cholesterol. Efforts at reducing the level of cholesterol in intact chicken eggs have included genetic selection, use of low fat and high fiber diets, administration of pharmacological agents and various egg selection methods. Many of these methods are tedious and others have not led to large decreases in egg cholesterol. An animal food composition effective in reducing the amount of cholesterol in an egg and a method of producing low cholesterol eggs are therefore needed. The present invention addresses these needs.
The present invention relates to an animal food composition including an animal food and an HMG-CoA reductase inhibitor. The animal food composition is preferably an oviparous vertebrate food composition. The animal food composition is effective in reducing the amount of cholesterol in an egg. The HMG-CoA reductase inhibitor is preferably a compound having the following formula:
wherein
R1 is C3-10cycloalkyl; C1-10alkyl provided that the C1-10alkyl is not 1-methylpropyl if R2 and R3 are both methyl groups; C1-10CF3-substituted alkyl; phenyl; halophenyl; phenyl-C1-3 alkyl; substituted phenyl-C1-3alkyl in which the substituent is halo, C1-3alkyl or C1-3alkoxy;
R2 is H, C1-10alkyl, or hydroxyl;
R3 is H, C1-10alkyl;
the dotted lines at X, Y and Z represent possible double bonds, said double bonds when present being either X and Z in combination or X, Y or Z alone;
or the corresponding dihydroxy acid, a pharmaceutically acceptable salt of said acid, a C1-4alkyl ester of said acid, a phenyldimethylamino-substituted-C1-4alkyl ester of said acid or an acetylamino-substituted-C1-4alkyl ester of said acid.
In yet another embodiment of the present invention, the HMG-CoA reductase inhibitor is a compound of the following formula:
wherein
X is —CH2—, —CH2CH2—, —CH2CH2CH2— or —CH2CH(CH3)—;
R1 is 1-naphthyl; 2-naphthyl; cyclohexyl; norbornenyl; 2-, 3-, or 4-pyridinyl; 2-, 3- or 4-pyridinyl-N-oxide; 2-, 3- or 4-(N—C1-4alkyl) pyridinium halide; phenyl; phenyl substituted with halogen, hydroxyl, trifluoromethyl, C1-4alkyl, C1-4alkoxy, C2-8 alkanoyloxy; C1-8alkyl;
R2 and R3 are independently hydrogen; cyano; trifluoromethyl; phenyl; C1-4alkyl; C2-8 carboalkoxy; CH2OR7 where R7 is hydrogen, C1-6alkanoyl, —CONHR8 where R8 is a C1-6 alkyl, phenyl or phenyl substituted with halogen or C1-4alkyl; halogen provided that if R1 is 1-methylethyl, R4 is 4-fluorophenyl and either of R2 or R3 is bromine, the other of R2 or R3 is not bromine; or
either of R2 or R3 is —CONR5R6 where R5 and R6 are independently hydrogen; C1-6 alkyl; 2-, 3- or 4-pyridinyl; phenyl; phenyl substituted with halogen, cyano, trifluoromethyl or C3-8-carboalkoxy; and the other of R2 or R3 is hydrogen; C1-6alkyl; cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl; phenyl; phenyl substituted with halogen, hydroxyl, trifluoromethyl, C1-4alkyl, C1-4alkoxy, or C2-8alkanoyloxy; and
R4 is C1-6alkyl, cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl; trifluoromethyl; phenyl; or phenyl substituted with halogen;
or the corresponding dihydroxy acid.
In yet another embodiment of the invention, a method of lowering the amount of cholesterol in an egg is provided that includes administering to an egg-laying animal an effective amount of the above-described compounds. The method is preferably carried out with chickens but may be carried out with any oviparous vertebrate, including turkey, geese, quail, rattites (including ostriches, emus and rheas) turtles and fish.
In a further embodiment of the present invention, an egg produced by the above-method is also described.
FIG. 1 is a graph showing hepatic microsomal HMG-CoA reductase activity in control (n=10) and statin-treated (n=5) laying hens on day 35 of the study. Values are mean±SD. Bars with similar letters are not significantly different (P>0.05).
FIG. 2 is a graph showing hepatic microsomal cholesterol 7α-hydroxylase activity in control (n=10) and statin-treated (n=5) laying hens on day 35 of the study. Values are mean±SD. Bars with similar letters are not significantly different (P>0.05).
FIG. 3 represents a northern blot analysis of hepatic microsomal triglyceride transport protein (MTP) large subunit, protein disulfide isomerase (PDI), HMG-CoA reductase (HMGR), and apolipoprotein B (apoB) mRNA in control (numbers 1-10) and statin-treated (numbers 11-40) laying hens. Each lane contained 20 μg total RNA. Differences in loading and/or RNA transfer are accounted for by hybridization with an 18S cDNA. Approximate sizes of the mRNAs were: MTP, 1.4 kb; PDI, 2.7 kb; HMGR, 4.0 kb; apoB, 14 kb; and 18S, 1.8 kb. Because of the large size of the apoB mRNA, total RNA was separated on an additional agarose gel (0.8%), transferred, and probed, whereas MTP, PDI, and HMGR signals were visualized by sequential probing and stripping of the same membrane replica of a 1% agarose gel.
FIG. 4 is a graph showing the comparative effects of atorvastatin (A), lovastatin (L), and simvastatin (S) on hepatic microsomal triglyceride transport protein (MTP) large subunit, protein disulfide isomerase (PDI), HMG-CoA reductase (HMGR), and apolipoprotein B (apoB) mRNA. The individual autoradiographs depicted in FIG. 3 used to create FIG. 4 were digitally scanned (Epson Model ES-1200C scanner) and the signals were quantitated using SigmaGel (Version 1.0; Jandel Scientific, San Rafael, Calif.) and normalized by the abundance of 18S rRNA on each membrane. Values are mean±SD (n=10 for controls; 5 for each statin group). For the MTP and apoB transcripts, bars with similar letters are not significantly different (P>0.05).
FIG. 5 depicts a graph showing plasma total cholesterol concentrations of control (n=10) and HMG-CoA reductase inhibitor-treated (n=5) laying hens. Birds were fasted for 15 hours prior to blood collection on day 35 of the study. Values are mean±SD. Bars with similar letters are not significantly different (P>0.05).
FIG. 6 is a graph showing plasma triglyceride concentrations (glycerol-corrected) of control (n=10) and HMG-CoA reductase inhibitor-treated (n=5) laying hens. Values are mean±SD. Birds were fasted for 15 hours prior to blood collection on day 35 of the study. Bars with similar letters are not significantly different (P>0.05).
FIG. 7 depicts a sodium dodecyl sulfate (SDS) polyacrylamide gel (4.5-18% gradient gel) with whole yolk extracts from control hens and HMG-CoA reductase inhibitor-treated hens. Lane 1 contained protein standards (molecular weights [kDa] are indicated); lanes 2 and 9 contained yolk extracts from control hens; lanes 3 to 8 contained yolk extracts from hens fed 0.03% atorvastatin, 0.06% atorvastatin, 0.03% lovastatin, 0.06% lovastatin, 0.03% simvastatin, and 0.06% simvastatin, respectively. Lane 10 contained yolk VLDL. Each lane contained 12 μg of protein. The gel was stained with Coomassie Brilliant Blue R-250 containing 20 mM AlCl3 in order to visualize the phosvitin bands (˜37-45 kDa). The position of the largest VLDL apolipoprotein B fragment is indicated by an asterisk, while the position of lipovitellin I, the largest major vitellogenin (VTG) fragment, is indicated by a plus sign. For a complete description of all bands present in whole egg yolk, see Elkin et al., Comp. Biochem. Physiol. 112B:191-196 (1995).
For the purposes of promoting an understanding of the principles of the invention, reference will now be made to preferred embodiments and specific language will be used to describe the same. It will nevertheless be understood that no limitation of the scope of the invention is thereby intended, such alterations and further modifications of the invention, and such further applications of the principles of the invention as illustrated herein, being contemplated as would normally occur to one skilled in the art to which the invention relates.
As described above, the present invention relates to an animal food composition effective in reducing the cholesterol content of an egg, a method of reducing the cholesterol content of an egg and an egg having a decreased amount of cholesterol produced by the method. The compounds used in the method are inhibitors of the rate-limiting enzyme in cholesterol biosynthesis, HMG-CoA reductase, and are preferably members of the class of drugs known as statins. The inhibitors are advantageously administered to poultry, especially chickens.
In one aspect of the invention, an animal food composition effective in reducing the amount of cholesterol in an egg includes an animal food and a compound with a substituted polyhydronapthalene nucleus having the following formula (I):
R1 is C3-10cycloalkyl; C1-10alkyl provided that the C1-10alkyl is not 1-methylpropyl if R2 and R3 are both methyl groups; C1-10CF3-substituted alkyl; phenyl, halophenyl; phenyl-C1-3 alkyl; substituted phenyl-C1-3alkyl in which the substituent is halo, C1-3alkyl or C1-3alkoxy;
R2 is H, C1-10alkyl, or hydroxyl;
R3 is H, C1-10alkyl; and
the dotted lines at X, Y and Z represent possible double bonds, said double bonds when present being either X and Z in combination or X, Y or Z alone; or the corresponding dihydroxy acid of the formula (II):
or a pharmaceutically acceptable salt of said acid, a C1-4alkyl ester of said acid, a phenyldimethylamino-substituted-C1-4alkyl ester of said acid or an acetylamino-substituted-C1-4alkyl ester of said acid.
R2 is further preferably a methyl group or a hydroxyl group and R1 is further preferably 1,1-dimethylpropyl. R1 may be 1-methylpropyl unless R2 and R3 are both methyl groups. R3 is advantageously a methyl group. The compound is further preferably a 2,2-dimethylbutyric acid 8-ester with (4R,6R)-6-[2-[1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl]ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one (simvastatin). Other preferred embodiments are delineated in U.S. Pat. Nos. 3,983,140; 4,049,495; 4,231,938; 4,346,227; 4,432,996; and 4,444,784.
The compounds, including ML-236B (wherein R1 is 1-methylpropyl, R2 is hydrogen and R3 is a methyl group) and its derivatives, may be isolated and purified from fungi as known in the art and as shown in U.S. Pat. Nos. 3,983,140; 4,049,495; 4,231,938; 4,346,227; and 4,432,996 which are hereby incorporated by reference in their entirety. The compounds shown above may also be synthesized by methods known in the art and as described in U.S. Pat. No. 4,444,784 and U.S. patent application Ser. No. 118,050 filed Feb. 4, 1980 which are also hereby incorporated by reference in their entirety.
As used herein, the following terms have the following meanings:
alkyl means a saturated or unsaturated aliphatic hydrocarbon which may be either straight chain or branched and includes methyl, ethyl and structural isomers of propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl.
Alkoxy means an alkyl group as defined above attached to an oxygen atom. Carboalkoxy means an alkoxy group as defined above attached through the oxygen atom to a carbonyl group.
Norbornenyl means a group derived by the removal of a hydrogen atom (other than at a bridgehead carbon atom) from bicyclo[2.2.1]hept-2-ene.
Alkanoyloxy means an alkyl group attached to a carbonyl group which is attached to an oxygen atom.
In yet another embodiment of the present invention, the animal food composition includes compounds I and II above having the following configuration (III):
wherein R1, R2 and R3 are as defined for compound I above; or the corresponding dihydroxy acid having the following configuration (IV):
or a pharmaceutically acceptable salt of said diydroxy acid, a C1-4alkyl ester of said dihydroxy acid, a phenyldimethylamino-substituted-C1-4alkyl ester of said dihydroxy acid or an acetylamino-substituted-C1-4alkyl ester of said dihydroxy acid.
In yet another embodiment of the invention, the animal food composition includes a compound having a substituted pyrrole of the following formula (V):
wherein
X is —CH2—, —CH2CH2—, —CH2CH2CH2— or —CH2CH(CH3)—;
R1 is 1-naphthyl; 2-naphthyl; cyclohexyl; norbornenyl; 2-, 3-, or 4-pyridinyl; 2-, 3- or 4-pyridinyl-N-oxide; 2-, 3- or 4-(N—C1-4alkyl) pyridinium halide; phenyl; phenyl substituted with halogen, hydroxyl, trifluoromethyl, C1-4 alkyl, C1-4 alkoxy, C2-8 alkanoyloxy; C1-8 alkyl;
R2 and R3 are independently hydrogen; cyano; trifluoromethyl; phenyl; C1-4alkyl; C2-8 carboalkoxy; CH2OR7 where R7 is hydrogen; C1-6alkanoyl, —CONHR8 where R8 is a C1-6 alkyl, phenyl or phenyl substituted with halogen or C1-4alkyl; halogen provided that if R1 is 1-methylethyl, R4 is 4-fluorophenyl and either of R2 or R3 is bromine, the other of R2 or R3 is not bromine; or
either of R2 and R3 is —CONR5R6 where R5 and R6 are independently hydrogen; C1-6 alkyl; 2-, 3- or 4-pyridinyl; phenyl; phenyl substituted with halogen, cyano, trifluoromethyl or C3-8carboalkoxy; and the other of R2 or R3 is hydrogen; C1-6alkyl; cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl; phenyl; or phenyl substituted with halogen, hydroxyl, trifluoromethyl, C1-4alkyl, C1-4alkoxy, or C2-8alkanoyloxy; and
R4 is C1-6alkyl, cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl; trifluoromethyl; pheny; or phenyl substituted with halogen;
or a pharmaceutically acceptable salt thereof.
X is preferably a methylene (—CH2CH2—) group. R1 is preferably a C1-3alkyl group and is further preferably 1-methylethyl. Furthermore, R2 is preferably —CONR5R6, R5 is preferably hydrogen and R6 is a preferably a phenyl group. R4 is advantageously a substituted phenyl, preferably 4-fluorophenyl. Moreover, R3 is preferably a phenyl group. R2 and R3 may also both be methylene groups joined together in a ring through 3 or 4 methylene groups or through an oxygen atom. R2 and R3 may also both be carbonyl groups and may be joined together in a ring through a nitrogen atom. The nitrogen atom is further attached to a hydrogen, a C1-4 alkyl, or a benzyl group. In yet another aspect of the invention, R2 is —COR9, R3 is —COR10 and R9 and R10 are attached to each other to form a ring. R9 and R10 are each a nitrogen atom and each nitrogen atom is independently attached to hydrogen, C1-4alkyl, or a benzyl group. Other preferred embodiments are delineated in U.S. Pat. Nos. 4,647,576; 4,681,893 and 5,273,995.
Compound V is further preferably (βR,δR)-2-(p-fluorophenyl)-β,δ-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoic acid) (atorvastatin). The lactone form of atorvastatin is (2R-trans)-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide.
In a further embodiment of the invention, compounds V and VI preferably have the following configuration (VII):
wherein R1, R2, R3 and R4 are as defined for compounds V and VI;
or a pharmaceutically acceptable salt thereof.
wherein R1, R2, R3 and R4 are as defined for compounds V and VI;
or a pharmaceutically acceptable salt thereof.
The substituted pyrroles may be synthesized by methods known in the art as described in U.S. Pat. Nos. 4,647,576,; 4,681,893; 5,273,995 and as similarly described in Roth, B. D. et al., J. Med. Chem. 34:357-366 (1991), all hereby incorporated by reference in their entirety.
The present invention can use any compatible animal food, including dry animal food. The composition of the animal food is not a critical part of the invention, but will depend on the egg-laying animal it will be administered to. Suitable animal foods are readily available commercially. The animal food is preferably an oviparous vertebrate animal food. If the egg-laying animal is a chicken, the composition may typically include, for example, corn and soybean meal (about 66.15% and about 21.29% by weight, respectively). The chicken food may also contain, on a weight percent basis, about 1.75% alfalfa meal, about 1.50% dicalcium carbonate, about 5.38% calcium carbonate, about 2.74% oyster shell, about 0.45% sodium chloride, about 0.25% vitamins and trace minerals, about 1% soybean oil, about 0.06% of a methionine hydroxy analogue (calcium), about 0.1% of an antioxidant and about 0.05% of a mold inhibitor. The vitamin and trace mineral mix may be any such mix as known in the art, such as the mix of DI-Egg (Dawe's Laboratories, Chicago Ill.). Any antioxidant known in the art may be used, such as that sold under the name Dry Polyanox from Agrimerica, Inc., Northbrook, Ill. The mold inhibitor includes typical inhibitors known in the art, such as those purchased from Agrimerica under the name of Dry Mold-Chek Plus 5762. It will be recognized that certain components in the diet may be removed and other components added, depending on the situation. Moreover, it will be recognized that the relative proportions of the compounds in the animal food mixture may be increased or decreased depending on the situation. Animal food compositions for other oviparous vertebrates are well known in the art.
In one aspect of the invention, the method includes administering to an egg-laying animal an amount of a cholesterol-reducing component effective in reducing the amount of cholesterol in an egg. The cholesterol-reducing component is preferably an HMG-CoA reductase inhibitor.
The HMG-CoA reductase inhibitor is typically added to the food of the animal in a quantity that will reduce the level of cholesterol in an egg. The inhibitor is typically included in the food by methods known in the art, including adding the inhibitor directly to the food or to a carrier with subsequent addition of the carrier/inhibitor mixture to the food. For example, the inhibitor may be mixed with a vegetable oil and the vegetable oil/inhibitor mixture may be mixed into the food. As a further example, the inhibitor may be mixed with an organic solvent, the inhibitor/solvent mixture may be mixed with the food and the organic solvent is then allowed to volatilize. The inhibitor will preferably reduce the amount of cholesterol in the yolk of an egg by at least about 5%, 10%, 15%, 20%, 25% and 30% per gram of yolk. The amount of inhibitor will most preferably reduce the amount of cholesterol in the yolk of an egg by at least about 35% per gram of yolk. The amount of inhibitor required to reduce the cholesterol in an egg will vary depending on factors including the potency of the inhibitor, egg size and the rate of biological degradation of the inhibitor. However, the quantity of inhibitor typically administered is in the range of about 5 mg/animal/day to about 265 mg/animal/day, preferably about 15 mg/animal/day to about 150 mg/animal/day, further preferably about 25 mg/animal/day to about 100 mg/animal/day and most preferably about 30 mg/animal/day to about 60 mg/animal/day. The dosage is based on the animal eating about 100 g of food/day. Therefore, to administer about 30 mg/animal/day of the inhibitor, the food must be supplemented with about 0.03% by weight of the inhibitor. The inhibitor may be administered over the entire laying cycle (e.g., about 20 to about 70 weeks of age) and subsequent cycles. Depending on the inhibitor and the dosage of the inhibitor, initial decreases in egg cholesterol may be seen after about 7 to about 42 days after the dose regimen has begun. However, larger daily doses may be required if it is desired to obtain cholesterol reduction in a shorter period of time. It must be recognized that, if the doses are large enough to completely inhibit cholesterol synthesis, steroid hormone production could be impaired which would result in the failure of the animal to lay eggs.
The method is particularly advantageous in lowering the level of cholesterol in chicken eggs. However, the method of reducing the level of cholesterol may be applied to any oviparous vertebrate, including geese, turkey, quail, rattites (including ostriches, emus and rheas), turtles and fish.
Reference will now be made to specific examples using the above described processes. It is to be understood that the examples are provided to more completely describe preferred embodiments, and that no limitation to the scope of the invention is intended thereby. It is to be noted that analysis of variance, as described in Steel, R. G. D. and Torrie, J. H., Principles and Procedures of Statistics: A Biometrical Approach, 2nd ed. McGraw-Hill, New York, N.Y., 137-171;187-188, 1980, was performed on all data using the General Linear Models procedure of the SAS® Institute as described in SAS/STAT User's Guide, Version 6, 4th ed., vol. 2, SAS Institute, Inc., Cary, N.C., 891-996, 1989. In certain instances, single degree of freedom linear contrasts were also performed as described in the above Steel and Torrie reference. Individual treatment differences were tested by Duncan multiple range test as described in the above Steel and Torrie reference. Differences at P<0.05 were considered significant. Moreover, the hens initial body weights in the Examples that follow ranged from 1,556 g to 1,646 g (P>0.05) and, during the course of the 5-week study, the birds gained between 67 g and 137 g (data not shown). Feed intakes did not differ (P>0.05) among treatments and ranged from 99-106 g/bird/day (data not shown). Thus, since the HMG-CoA reductase inhibitors were fed at dietary levels of 0.03% or 0.06%, all treated hens consumed approximately 30 or 60 mg of compound/bird/day, respectively. On a body weight basis, this equated to daily doses of approximately 19 or 38 mg HMG-CoA reductase inhibitor/kg body weight.
Forty, 18-month-old, White Leghorn hens were obtained from the flock maintained at the Purdue University Poultry Research Center. Each hen was placed in an individual 30×35×45 cm slant-back cage in an environmentally controlled room (24° C. and 16 h of light daily) and birds were assigned to one of the seven dietary treatments (see below) on the basis of both egg production and average egg weight during the 10 days immediately prior to the initiation of the experiment. Ten control hens were fed a corn-soybean meal-based layer ration as described in Elkin, R. G., and J. C. Rogler, J. Agric. Food Chem. 38:1635-1641, 1990, containing 0.06% avicel® microcrystalline cellulose (FMC Corp., Philadelphia, Pa.) (diet 1) while five hens each were fed the same ration supplemented, at the expense of avicel®, with 0.03% atorvastatin (diet 2), 0.06% atorvastatin (diet 3), 0.03% lovastatin (diet 4), 0.06% lovastatin (diet 5), 0.03% simvastatin (diet 6), or 0.06% simvastatin (diet 7). The two levels of each drug equated to a daily dosage of approximately 30 or 60 mg/hen, respectively, based on a daily feed intake of 100 g/bird. Feed and water were supplied for ad libitum consumption throughout the 35-day experiment, and feed intake, egg production, and egg weights were recorded daily on an individual basis. On day 35, all of the hens were fasted for 15 hours and individual blood samples were obtained by cardiac puncture using heparinized 12-cc syringes with 18 gauge needles. Immediately after procurement of a blood sample, each hen was euthanitized by cervical dislocation. Its entire liver was then removed, weighed, and sectioned in order to provide samples for subsequent biochemical, enzymatic, and Northern blot analyses. In addition, a portion of the left liver lobe was collected from each hen and fixed in 10% buffered formalin. The tissues were embedded in paraffin, sectioned at 5 μm, stained with hematoxylin and eosin, and examined microscopically by light microscopy. The above protocol was approved by the Purdue University Animal Care and Use Committee.
Atorvastatin was provided by Parke-Davis. The drug was synthesized as described in Roth, et al., J. Med. Chem., 34:357-366, 1991. Lovastatin (Merck, Sharp & Dohme) was prepared by extracting formulated capsules of Mevacor as described in Bocan, Biochim. Biophys. Acta, 1123:133-144, 1992, whereas simvastatin was provided by Merck, Sharp & Dohme.
Hens were treated as described in Example 1. One egg from each hen was collected on days 0, 7, 14, 21, 28, and 35. The eggs were hard-cooked, and the yolks were separated, weighed, and crumbled. A 1-g sample of each yolk was homogenized with 15 ml of chloroform-methanol 2:1 (by vol.), sonicated, and filtered as described in Elkin, R. G. and Rogler, J. C., J. Agric. Food Chem. 38:1635-1641, 1990. Egg homogenate filtrates were analyzed for cholesterol as described in Rudel, L. L. and Morris, M. D., J. Lipid Res. 14:364-366 (1973). The results are shown in Table 1.
TABLE 1 |
Yolk cholesterol contents of eggs from control and statin-treated laying hens |
Treatment | % of Diet | Week 0 | Week 1 | Week 2 | Week 3 | Week 4 | Week 5 |
mg cholesterol/g yolk |
Control | — | 11.6 ± 0.2a | 11.9 ± 0.1a | 11.5 ± 0.1a | 11.7 ± 0.1a | 11.6 ± 0.1a | 11.6 ± 0.2a |
Atorvastatin | 0.03 | 11.4 ± 0.3a | 9.4 ± 0.3c | 8.7 ± 0.2e | 8.6 ± 0.2c | 8.3 ± 0.1d | 8.2 ± 0.2d |
Atorvastatin | 0.06 | 11.3 ± 0.3a | 9.3 ± 0.2c | 7.8 ± 0.3f | 7.5 ± 0.1f | 7.5 ± 0.1c | 7.6 ± 0.2d |
Lovastatin | 0.03 | 11.0 ± 0.2a | 10.7 ± 0.2b | 11.1 ± 0.2a,b | 10.8 ± 0.2b | 10.9 ± 0.2a,b | 10.8 ± 0.1b |
Lovastatin | 0.06 | 10.9 ± 0.1a | 10.7 ± 0.1b | 10.8 ± 0.1b,c | 10.5 ± 0.1b,c | 10.9 ± 0.2a,b | 10.8 ± 0.1b |
Simvastatin | 0.03 | 10.8 ± 0.2a | 11.2 ± 0.2a,b | 10.3 ± 0.2c,d | 10.0 ± 0.1c,d | 10.3 ± 0.2b,c | 10.1 ± 0.1b |
Simvastatin | 0.06 | 11.0 ± 0.3a | 10.7 ± 0.2b | 10.0 ± 0.1d | 9.8 ± 0.1d | 9.9 ± 0.3c | 9.3 ± 0.1c |
mg cholesterol/yolk |
Control | 196.6 ± 3.6a | 198.3 ± 4.3a | 193.1 ± 3.9a | 198.8 ± 4.3a | 199.7 ± 3.0a | 201.5 ± 5.8a | |
Atorvastatin | 0.03 | 203.2 ± 7.7a | 161.7 ± 5.5b,c | 141.1 ± 3.3c | 143.7 ± 3.3c | 134.3 ± 2.2c | 137.2 ± 3.8d |
Atorvastatin | 0.06 | 191.9 ± 7.3a | 149.7 ± 3.8c | 105.3 ± 4.3d | 104.0 ± 3.7d | 104.2 ± 2.3d | 107.9 ± 3.9e |
Lovastatin | 0.03 | 195.7 ± 6.8a | 192.2 ± 6.5a | 193.8 ± 6.6a | 192.3 ± 5.1a | 193.9 ± 4.2a | 193.6 ± 4.0a,b |
Lovastatin | 0.06 | 197.8 ± 4.3a | 185.5 ± 8.4a,b | 186.6 ± 5.3a,b | 184.6 ± 5.1a,b | 187.1 ± 7.2a,b | 186.9 ± 4.3a,b |
Simvastatin | 0.03 | 189.7 ± 6.1a | 192.9 ± 5.3a | 174.6 ± 4.2a,b | 166.2 ± 2.7b | 174.6 ± 2.7b | 172.1 ± 2.9b,c |
Simvastatin | 0.06 | 191.1 ± 7.9a | 188.7 ± 9.1a,b | 170.8 ± 3.0b | 166.0 ± 4.6b | 170.4 ± 7.0b | 158.0 ± 2.7c,d |
Values are mean ± SEM for duplicate analyses of one egg per hen per week from 10 (control) or 5 (vastatin treatments) hens. | |||||||
a-fWithin a column, means with different superscripts are significantly different (P ≦ 0.05). |
As seen in Table 1, significant decreases in yolk cholesterol contents vs. controls, on both a per g of yolk and a per yolk (egg) basis, were noted in both atorvastatin-fed groups after only seven days of treatment (9.4 and 9.3 vs. 11.9 mg/g yolk and 161.7 and 149.7 vs. 198.3 mg/yolk, respectively). By week 2, eggs from the low dose and high dose atorvastatin-treated hens contained 27% and 45% less total yolk cholesterol than those of control eggs (141.1 and 105.3 vs. 193.1 mg/yolk, respectively). These reductions were maintained throughout the duration of the study such that by week 5, total yolk cholesterol contents of 137.2 mg (0.03% dose) and 107.9 mg (0.06% dose) were observed. The latter figure, a 46% reduction from the control level of 201.5 mg cholesterol/egg (week 5), is of a magnitude never before reported, and was accounted for by a 19% decrease in yolk weight (see Table 2) combined with a 35% reduction in the amount of cholesterol per g of yolk. Simvastatin also depressed yolk cholesterol levels, but to a much lesser degree than atorvastatin. As compared to controls, maximal yolk cholesterol reductions of 20% on a mg/g basis (9.3 vs. 11.6, respectively) and 22% on a per yolk basis (158.0 vs. 201.5, respectively) were observed in hens fed 0.06% simvastatin. Lovastatin was the least efficacious of the three statins, as evidenced by maximal yolk cholesterol reductions of 7% on a mg/g basis (10.8 vs. 11.6, respectively) and 7% on a per yolk basis (186.9 vs. 201.5, respectively) in hens fed the higher dose.
Hens were treated as described in Example 1. Egg yolk was weighed as outlined in Example 2. The results are shown in Table 2.
TABLE 2 |
Egg production, egg weights, and yolk weights of control and statin-treated laying hens |
Treatment | % of Diet | Week 1 | Week 2 | Week 3 | Week 4 | Week 5 | Overall |
Hen-day egg production, % |
Control | — | 84.3 ± 0.9b,c,d | 84.3 ± 0.5b | 88.6 ± 0.7a | 90.0 ± 1.3a | 82.9 ± 1.7b | 85.1 ± 1.7a (298) |
Atorvastatin | 0.03 | 82.9 ± 1.8c,d | 68.6 ± 1.0c | 80.0 ± 2.0b | 77.1 ± 1.2c | 77.1 ± 1.2c,d | 75.4 ± 4.1b,c (132) |
Atorvastatin | 0.06 | 82.9 ± 1.0c,d | 60.0 ± 1.8d | 68.6 ± 1.8c | 68.6 ± 1.8d | 74.3 ± 1.0d | 69.1 ± 3.5c (121) |
Lovastatin | 0.03 | 91.4 ± 1.2a | 88.6 ± 1.0a | 85.7 ± 1.0a | 88.6 ± 1.8a | 88.6 ± 1.0a | 88.6 ± 2.4a (155) |
Lovastatin | 0.06 | 88.6 ± 1.0a,b | 85.7 ± 1.5a,b | 88.6 ± 1.0a | 88.6 ± 1.8a | 91.4 ± 1.2a | 88.6 ± 2.9a (155) |
Simvastatin | 0.03 | 80.0 ± 2.5d | 85.7 ± 1.5a,b | 80.0 ± 1.2b | 80.0 ± 1.2b,c | 80.0 ± 1.2b,c | 80.6 ± 2.3a,b (141) |
Simvastatin | 0.06 | 85.7 ± 1.5b,c | 82.9 ± 1.0b | 77.1 ± 1.2b | 82.9 ± 1.0b | 88.6 ± 1.0a | 82.3 ± 1.9a,b (144) |
Egg weight, g |
Control | — | 64.4 ± 0.5a | 64.7 ± 0.5a | 64.3 ± 0.5a,b | 64.9 ± 0.5a,b | 64.7 ± 0.7a | 64.6 ± 1.1a (298) |
Atorvastatin | 0.03 | 63.0 ± 0.7a | 61.2 ± 0.8c,d | 60.5 ± 0.8c | 60.3 ± 0.7d | 61.0 ± 0.7b | 61.3 ± 1.0a,b (132) |
Atorvastatin | 0.06 | 63.6 ± 0.8a | 59.5 ± 1.0d | 56.9 ± 0.7d | 56.8 ± 0.7c | 57.8 ± 0.7c | 58.9 ± 0.9b (121) |
Lovastatin | 0.03 | 64.9 ± 0.7a | 64.3 ± 0.8a,b | 65.1 ± 0.7a | 65.8 ± 0.6a | 64.7 ± 0.7a | 65.0 ± 1.4a (155) |
Lovastatin | 0.06 | 62.6 ± 1.9a | 64.0 ± 0.7a,b | 65.3 ± 1.1a | 63.3 ± 0.8b,c | 62.9 ± 0.8a,b | 63.8 ± 1.8a (155) |
Simvastatin | 0.03 | 63.8 ± 1.0a | 63.9 ± 0.9a,b | 62.5 ± 0.7b,c | 62.8 ± 0.7b,c | 62.9 ± 0.7a,b | 63.3 ± 1.4a,b (141) |
Simvastatin | 0.06 | 63.8 ± 1.0a | 62.0 ± 1.0b,c | 61.0 ± 1.0c | 62.2 ± 1.0b | 60.5 ± 0.8b | 62.0 ± 1.9a,b (144) |
Yolk weight, g |
Control | — | 16.6 ± 0.4a | 16.8 ± 0.3a | 17.0 ± 0.4a | 17.2 ± 0.3a,b | 17.3 ± 0.4a | 17.0 ± 0.2a (50) |
Atorvastatin | 0.03 | 17.2 ± 0.3a | 16.2 ± 0.3a | 16.7 ± 0.4a | 16.2 ± 0.2b | 16.6 ± 0.3a | 16.6 ± 0.1a (25) |
Atorvastatin | 0.06 | 16.1 ± 0.3a | 13.4 ± 0.3b | 13.9 ± 0.5b | 13.9 ± 0.3c | 14.2 ± 0.4b | 14.3 ± 0.2b (25) |
Lovastatin | 0.03 | 17.9 ± 0.7a | 17.4 ± 0.8a | 17.8 ± 0.5a | 17.8 ± 0.4a | 17.8 ± 0.5a | 17.7 ± 0.2a (25) |
Lovastatin | 0.06 | 17.4 ± 1.0a | 17.3 ± 0.7a | 17.7 ± 0.6a | 17.2 ± 0.9a,b | 17.3 ± 0.7a | 17.4 ± 0.3a (25) |
Simvastatin | 0.03 | 17.2 ± 0.5a | 17.0 ± 0.3a | 16.7 ± 0.4a | 17.0 ± 0.5a,b | 17.1 ± 0.3a | 17.0 ± 0.2a (25) |
Simvastatin | 0.06 | 17.5 ± 0.8a | 17.2 ± 0.4a | 16.9 ± 0.5a | 17.2 ± 0.4a,b | 17.0 ± 0.3a | 17.2 ± 0.2a (25) |
Values are mean ± SEM of 10 (control) or 5 (statin treatments) hens. Hen-day egg production was calculated as (100 × number of eggs laid)/(number of hens × days). For the 10 days immediately preceding the commencement of the study, the average hen-day egg production, egg weights, and yolk weights for each treatment group were 86%, 65.0 g, and 17.5 g, respectively. Number of eggs or yolks for each overall mean (weeks 1-5) are in parentheses. | |||||||
a-dWithin a column, means with different superscripts are significantly different (P ≦ 0.05). |
As seen in Table 2, overall hen-day egg production was significantly depressed only in the atorvastatin-treated groups as compared to that of control birds, with maximal reductions at each level observed by week 2. The rate of lay actually increased thereafter and, by week 5, production rates of the low- and high-dose atorvastatin-treated birds were 93% and 90% that of controls, respectively. Although hens fed either level of atorvastatin or 0.06% simvastatin laid significantly smaller eggs than controls during weeks 2-5, overall egg weights were decreased (P≦0.05) only in the high-dose atorvastatin-treated birds. With regard to the latter group, maximal reductions in egg weights were noted by week 3. Overall yolk weights were also reduced (P≦0.05) only in birds fed 0.06% atorvastatin, with a maximal decrease observed during the second week of the study. Lovastatin treatment did not affect (P>0.05) any of the above production variables.
Plasma VLDL were isolated as described in Elkin, R G., and Schneider, W. J., Poult. Sci. 73:1127-1136 (1994), and the lipid composition of plasma VLDL was determined based on the extraction procedure of Slayback et al., Anal. Biochem., 83:372-384 (1977), and the HPLC method of Homan R., and Anderson, M. K., J. Chromatogr. B., 708:21-26, (1998).
In order to determine the VLDL particle size, a carbon-coated formvar grid was initially floated on a drop of each VLDL sample. If the sample was too concentrated, it was diluted (10-or 100-fold) in a buffer containing 0.15 M NaCl, 0.2 mM EDTA, 1 mM PMSF, and 5 μM leupeptin. After the grid floated on the drop for 5-10 minutes, the grid was removed and excess fluid drawn off with a piece of filter paper. The grid was then touched to 1% aqueous uranyl acetate and the excess stain removed with filter paper. Samples were examined in a JEOL JEM-100CX transmission electron microscope (JEOL, Tokyo, Japan) operating at 80 kV. Three representative micrographs were taken of each sample at a magnification 26,000×. Photographic positives of the negatives were made at an enlargement factor of 2.5× (82,500× final magnification) and the photographs were digitized at 600 dpi on a Hewlett-Packard Scanjet 4C flatbed scanner. Analysis of the digitized images was performed using Optimas 5.2 software (Optimas, Edmunds, Wash.). The feret diameter for a minimum of 500 particles was determined. All microscopic, photographic, and image analysis procedures were conducted without the operator's knowledge of the treatments from which the samples were obtained. The results are shown in Table 3.
TABLE 3 |
Diameters and compositions of plasma VLDL particles from control and statin-treated laying hens |
% of | Diameter | PE | Pro- | ||||||
Treatment | Diet | nm | EC | UC | TG | % | PC | SM | tein |
Control | — | 35.7 ± 0.1a (692) | 0.14 ± 0.03a | 3.22 ± 0.13a | 62.01 ± 1.36a | 4.27 ± 0.15a | 11.90 ± 0.32b | 0.90 ± | 17.56 ± |
0.09a | 0.80a | ||||||||
Atorvastatin | 0.03 | 34.9 ± 0.1a,b (838) | 0.03 ± 0.00b | 2.63 ± 0.26a | 61.35 ± 1.73a | 3.98 ± 0.25a | 14.12 ± 1.09a | 1.08 ± | 16.80 ± |
0.86a | 0.94a | ||||||||
Atorvastatin | 0.06 | 34.7 ± 0.1b (826) | 0.03 ± 0.01b | 2.05 ± 0.10b | 60.28 ± 2.93a | 3.10 ± 0.80a | 13.26 ± 0.64a,b | 0.00a | 21.29 ± |
3.49a | |||||||||
Lovastatin | 0.03 | 35.5 ± 0.1a,b (793) | 0.06 ± 0.01a,b | 2.94 ± 0.11a | 62.78 ± 1.01a | 3.76 ± 0.33a | 11.99 ± 0.18b | 1.08 ± | 17.37 ± |
0.31a | 0.70a | ||||||||
Lovastatin | 0.06 | 34.8 ± 0.1a,b (774) | 0.08 ± 0.02a,b | 3.03 ± 0.34a | 60.74 ± 1.22a | 3.46 ± 0.93a | 12.07 ± 0.82b | 0.66 ± | 19.96 ± |
0.23a | 1.32a | ||||||||
Simvastatin | 0.03 | 35.2 ± 0.1a,b (755) | 0.06 ± 0.02a,b | 2.84 ± 0.20a | 61.23 ± 2.98a | 3.96 ± 0.17a | 12.15 ± 0.58b | 1.77 ± | 17.99 ± |
1.24a | 1.48a | ||||||||
Simvastatin | 0.06 | 35.3 ± 0.1a,b (738) | 0.08 ± 0.04a,b | 2.97 ± 0.13a | 62.03 ± 1.53a | 3.65 ± 0.51a | 13.85 ± 0.61a,b | 0.36 ± | 17.06 ± |
0.23a | 0.84a | ||||||||
Values are mean ± SEM of plasma VLDL particles from 10 (control) or 5 (vastatin treatments) hens. For the particle diameter data, the average number of particles measured per hen per treatment appear in parentheses. Particle composition data are from single analyses of one plasma VLDL sample per hen per diet. EC, esterified cholesterol; UC, unesterified cholesterol; TG, triglyceride; PE, phosphatidylethanolamine; PC, phosphatidylcholine; SM, sphingomyelin. | |||||||||
a,bWithin a column, means with different superscripts are significantly different (P ≦ 0.05). |
As seen in Table 3, plasma VLDL particle diameters were reduced (P≦0.05) only in hens fed 0.06% atorvastatin, and the particles were richer in protein and contained 79% and 36% less esterified- and unesterified-cholesterol, respectively, than controls. Although the 0.03% dose of atorvastatin, as well as both doses of lovastatin and simvastatin, also significantly lowered VLDL-esterified cholesterol levels, they did not affect (P>0.05) the relative proportion of unesterified cholesterol, which was the major form of this sterol present in the VLDL particles. Moreover, the relative contents of triglyceride, phosphatidylethanolamine, sphingomyelin, and protein were not significantly affected by any of the vastatins. In contrast, phosphatidylcholine was elevated (P≦0.05) only in VLDL particles from hens fed 0.03% atorvastatin.
The birds were treated and samples were prepared as described in Example 1. One gram of each liver sample was homogenized with 12 ml of chloroform-methanol 2:1 (by vol.) and filtered directly into a 50 ml volumetric flask using a glass microfiber filter. Following re-homogenization and re-filtration, the liver filtrates were diluted to a final volume of 50 ml with chloroform-methanol 2:1 (by vol.) and analyzed for cholesterol content by the method of Rudel and Morris described in Example 2. The results are shown in Table 4 below.
TABLE 4 |
Weights and cholesterol contents of livers from control and statin-treated laying hens |
Liver Weight | Cholesterol |
Treatment | % of Diet | g | g/100 g BW | mg/g liver | mg/liver |
Control | — | 26.4 ± 0.9c | 1.61 ± 0.06b | 3.4 ± 0.04a | 88.7 ± 2.4a |
Atorvastatin | 0.03 | 30.9 ± 1.2b | 1.82 ± 0.05a,b | 2.8 ± 0.05c | 87.4 ± 2.2a |
Atorvastatin | 0.06 | 35.3 ± 2.3a | 2.02 ± 0.09a | 2.5 ± 0.07d | 89.7 ± 5.2a |
Lovastatin | 0.03 | 31.4 ± 1.4b | 1.81 ± 0.09a,b | 3.0 ± 0.05b,c | 95.7 ± 3.3a |
Lovastatin | 0.06 | 28.8 ± 0.9b,c | 1.76 ± 0.05b | 3.1 ± 0.07b | 90.2 ± 3.6a |
Simvastatin | 0.03 | 28.0 ± 1.7b,c | 1.65 ± 0.07b | 3.1 ± 0.10b | 86.8 ± 2.9a |
Simvastatin | 0.06 | 28.1 ± 0.6b,c | 1.64 ± 0.04b | 2.9 ± 0.04b,c | 82.6 ± 1.9a |
Values are mean ± SEM of 10 (control) or 5 (statin treatments) hens. Cholesterol data are from duplicate analyses of one tissue sample per hen. | |||||
a-cWithin a column, means with different superscripts are significantly different (P ≦ 0.05). |
As seen in Table 4, absolute liver weights were increased in all of the HMGR inhibitor-fed birds; however, when expressed on a relative body weight basis, only the organs of birds fed 0.06% atorvastatin were significantly larger than controls. Light microscopic examination of the livers of all hens in the study revealed no evidence of necrosis, fatty change, or inflammation (data not shown). In addition, no differences between experimental groups were noted.
Table 4 also shows that, although all of the HMGR inhibitor-treated groups had significantly lower cholesterol contents on a per g of tissue basis, liver total cholesterol values were unaffected (P>0.05) by dietary treatment when expressed on a whole organ basis.
In order to determine enyzme activities, liver microsomes were isolated by ultracentrifugation as described in Junker, L. H. and Story, J. A., Lipids 20:712-718, 1985 and stored in liquid nitrogen until use. Microsomal HMG-CoA reductase activity was determined by measuring the conversion of 14C-HMG-CoA to 14C-mevalonate as described in Shapiro, D. J., et al., Biochim. Biophys. Acta 370:369-377 (1974), while microsomal cholesterol 7α-hydroxylase activity was determined by measuring the incorporation of phospholipid liposome-solubilized 14C-cholesterol into 14C-7α-hydroxycholesterol as described in Junker, L. H. and Story, J. A., Lipids 20:712-718 (1985).
FIG. 1 shows that microsomal HMG-CoA reductase activities were significantly elevated 2- to 3-fold in the livers of all statin-fed animals vs. controls, while FIG. 2 shows that none of the HMG-CoA reductase inhibitors had a significant effect on hepatic microsomal cholesterol 7α-hydroxylase activity.
The hens were treated and samples were prepared as described in Example 1. Northern Blotting was performed to determine the effects of the HMG-CoA reductase inhibitors on the abundance of liver HMG-CoA mRNA as well as that of three other genes whose products play a key role in the hepatic synthesis of VLDL: apoB and the two components of the heterodimeric microsomal triglyceride transfer protein (MTP; ie., the large subunit and protein disulfide isomerase). Approximately 1 g of liver from each hen was homogenized in guanidinium thiocyanate solution (4M guanidinium thiocyanate, 25 mM sodium citrate [pH 7.4], 0.5% sarcosyl, and 0.1M β-mercaptoethanol) and total RNA extracted according as described in Chomczynski, P., and Sacchi, N., Anal. Biochem. 162:156-159 (1987). Total RNA (20 μg) was separated by electrophoresis on either a 0.8% or a 1% agarose gel according to Sambrook et al., Molecular Cloning, 2nd ed., Cold Spring Harbor Laboratory Press, Plainview, N.Y., 1.12 (1989) as modified by Tsang et al., Biotechniques 14:380-381 (1993). The integrity of the 28S and 18S rRNA was verified after staining with ethidium bromide and the gel was washed twice for 15 minutes in 1M ammonium acetate and transferred to a Genescreen membrane by capillary action. RNA cross-linking, pre-hybridization, hybridization, and wash steps were performed as described by Donkin et al., J. Molec. Endocrinol. 16:151-158 (1996). The abundance of target RNA was visualized on Kodak X-Omat AR film (Eastman Kodak Co., Rochester, N.Y.). Membranes were reprobed following stripping in 0.1×SSC and 1% SDS at 100° C. for 1 hour. Variations in loading and transfer of RNA were determnined using cDNA for rat 18S rRNA as described in Donkin et al., J. Molec. Endocrinol. 16:151-158 (1996).
The plasmid ChMTP, a full-length cDNA clone for the large subunit of chicken microsomal triglyceride transfer protein (MTP), was a gift from Dr. David A. Gordon (Department of Metabolic Diseases, Bristol-Myers Squibb, Princeton, N.J.). The 2.9 kb fragment cDNA was cloned into the BamHI/BamHi site of plasmid pcDNA-3.0 (Invitrogen, Carlsbad, Calif.). The plasmid CB13-1, a 960 bp fragment encoding the N-terminal part of chicken protein disulfide isomerase (PDI) described in Parkkonen et al., Biochem J. 256:1005-1011 (1988), was cloned into the EcoR1 site of pBR322 as described by Sambrook et al., Molecular Cloning, 2nd ed., Cold Spring Harbor Laboratory Press, Plainview, N.Y., 1.12 (1989), and was obtained from Dr. Erwin Ivessa (Department of Molecular Genetics, University of Vienna, Vienna, Austria). The plasmid HMGR #23, a 650 bp fragment containing the catalytic domain of chicken HMGR, was cloned into the Ncol and Pst 1 sites of the pGEM-T vector (Promega Corp., Madison, Wis.) and was provided by Dr. Elke Hengstschl{umlaut over (a)}ger-Ottnad (Department of Molecular Genetics, University of Vienna, Vienna, Austria). The plasmid pB2, a 1.2 kb fragment encoding part of the C-terminal portion of chicken apoB described in Kirchgessner, T. G., Gene 59:241-251 (1987), was cloned into the EcoRV sites of the pBluescript KS- vector (Stratagene, La Jolla, Calif.) and obtained from Dr. Madeline Douaire (Laboratoire de G{acute over (e)}n{acute over (e)}tique, Institut National de la Recherche Agronornique, Rennes Cedex, France). The plasmid pDF 8 containing a 1.1 kb BaniHI-EcoRI fragment corresponding to the central region of the rat 18S rRNA gene was kindly provided by Dr. Richard Torzynski (Cytoclonal Pharmaceuticals, Dallas, Tex.). This clone reacts with 18S rRNA from a number of species, including chicken, cow, and pig (S. S. Donkin, unpublished).
Insert cDNA was excised from the plasmids by restriction enzyme digestion, separated by electrophoresis through low melting temperature agarose, and purified by lithium chloride precipitation as describe in Favre, D. Biotechniques 13:24 (1992). DNA probes were labeled with 32P-labeled dCTP using the Ready-to-Go™ random oligonucleotide priming kit (Pharmacia Biotech, Inc., Piscataway, N.J.) to a specific activity of approximately 109 cpm/μg DNA.
In contrast to the more uniform responses in liver cholesterol content and microsomal HMGR activity among animals within each treatment group, there was considerable variation among individuals with regard to hepatic HMGR mRNA abundance as seen in FIG. 3 (in particular, note 0.03% atorvastatin-fed animals 11 and 12 vs. 13-15, 0.06% atorvastatin-fed animals 16 and 17 vs. 18-20, 0.03% lovastatin-fed animals 25 vs. 21, and 0.06% simvastatin-fed animals 36 vs. 38-40). Even more striking was the within- and between-treatment variability in the apoB and PDI mRNA levels, while MTP large subunit mRNA abundance appeared to be unaffected by statin treatment.
However, when the signals were normalized by the abundance of 18S rRNA, significant differences among dietary treatments were observed only for hepatic MTP and apoB mRNA as seen in FIG. 4. Single degree of freedom linear contrasts revealed the following differences (P≦0.05) for MTP large subunit: simvastatin>control, simvastatin>atorvastatin, and lovastatin>atorvastatin; and for apoB: control>lovastatin, control>simvastatin, atorvastatin>lovastatin, and atorvastatin>simvastatin.
Plasma samples obtained as described in Example 1 were analyzed for total cholesterol content according to the method of Rudel and Morris described in Example 2. Free glycerol-corrected total plasma triglyceride concentrations were determined using a commercial kit (Triglycerides-GB, Boehringer Mannheim Diagnostics, Indianapolis, Ind.).
FIG. 5 shows that plasma total cholesterol concentrations were lowered (P≦0.05) by both the 0.03% and 0.06% doses of atorvastatin (−56%, −63%) and simvastatin (−36%, −45%), while plasma triglycerides, as seen in FIG. 6 were depressed (P≦0.05) only with atorvastatin (−57%, −71%). Lovastatin did not significantly affect any of the plasma lipid variables.
In order to determine the yolk protein profiles, one fresh egg was collected from each hen on day 35 of the experiment. The yolk was carefully separated from the albumen using an egg separator and any adhering albumen was removed by rolling the yolk on a moist paper towel. The yolk membrane was then punctured with a forceps, and the yolk was gently squeezed out into a graduated cylinder and mixed with 5 vol of an ice-cold solution containing 20 mM Tris, 150 mM NaCl, 0.2 mM EDTA, 1 mM PMSF, and 5 μM leupeptin. Yolk protein contents were measured in the presence of 0.37% sodium dodecyl sulfate (SDS) based on the method of Lowry et al., J. Biol. Chem., 193:265-275 (1951), as modified by Elkin, R. G. and Schneider, W. J., Poult. Sci. 73:1127-1136 (1994). Egg yolk extracts were subjected to SDS-polyacrylamide gel electrophoresis (PAGE) on 4.5%-18% gradient gels under reducing conditions as described in the 1994 Elkin and Schneider, reference above. Following electrophoresis, the gels were stained with Coomassie Brilliant Blue R-250 containing 20 mM AlCl3, in order to visualize the phosvitin bands as described in Elkin, R. G., et al., Comp. Biochem. Physiol., 112B:191-196 (1995).
Representative yolk protein profiles of eggs from the statin-fed birds are shown in FIG. 7 (lanes 3-8) and appeared to be very similar to those of control hens (FIG. 7, lanes 2 and 9). This suggested that the proportion of VLDL relative to VTG, the other major yolk protein precursor, was not selectively reduced by HMGR inhibitor treatment of the hens.
While the invention has been illustrated and described in detail in the foregoing description, the same is to be considered as illustrative and not restrictive in character, it being understood that only the preferred embodiment has been described and that all changes and modifications that come within the spirit of the invention are desired to be protected.
Claims (12)
1. An animal feed composition effective in reducing the amount of cholesterol in an egg, comprising an oviparous vertebrate animal food and a cholesterol-reducing component selected from the group consisting of:
and;
c. a pharmaceutically acceptable salt of said dihydroxy acid.
2. The animal feed composition of claim 1, which is a bird feed.
3. The animal feed composition of claim 2, wherein said bird feed is chicken feed.
4. The animal feed composition of claim 1, wherein said cholesterol-reducing component is included in an amount effective to reduce the amount of cholesterol in said egg by at least about 10% per gram of yolk.
5. A method of reducing the amount of cholesterol in an egg, comprising administering to an egg-laying animal an amount of a cholesterol-reducing component effective in reducing the amount of cholesterol in said egg by at least about 10% per gram of yolk, said cholesterol-reducing component selected from the group consisting of:
and;
c. a pharmaceutically acceptable salt of said dihydroxy acid.
6. The method of claim 5, wherein said egg-laying animal is a bird.
7. The method of claim 6, wherein said bird is a chicken.
8. The method of claim 5, wherein said amount of cholesterol-reducing component is effective in reducing the amount of cholesterol in said egg by at least about 20% per gram of yolk.
9. The method of claim 5, wherein said component is administered orally to said egg-laying animal.
10. The method of claim 5, wherein said effective amount of said cholesterol-reducing component is about 15 mg/animal/day to about 150 mg/animal/day.
11. The method of claim 10, wherein said effective amount of said cholesterol-reducing component is about 30 mg/animal/day to about 60 mg/animal/day.
12. The method of claim 5, wherein said method includes adding said component to feed of the egg-laying animal and administering said feed to said egg-laying animal.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/162,522 US6177121B1 (en) | 1997-09-29 | 1998-09-29 | Composition and method for producing low cholesterol eggs |
US09/729,595 US20010006697A1 (en) | 1997-09-29 | 2000-12-04 | Composition and method for producing low cholesterol eggs |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6028697P | 1997-09-29 | 1997-09-29 | |
US09/162,522 US6177121B1 (en) | 1997-09-29 | 1998-09-29 | Composition and method for producing low cholesterol eggs |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/729,595 Division US20010006697A1 (en) | 1997-09-29 | 2000-12-04 | Composition and method for producing low cholesterol eggs |
Publications (1)
Publication Number | Publication Date |
---|---|
US6177121B1 true US6177121B1 (en) | 2001-01-23 |
Family
ID=26739781
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/162,522 Expired - Fee Related US6177121B1 (en) | 1997-09-29 | 1998-09-29 | Composition and method for producing low cholesterol eggs |
US09/729,595 Abandoned US20010006697A1 (en) | 1997-09-29 | 2000-12-04 | Composition and method for producing low cholesterol eggs |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/729,595 Abandoned US20010006697A1 (en) | 1997-09-29 | 2000-12-04 | Composition and method for producing low cholesterol eggs |
Country Status (1)
Country | Link |
---|---|
US (2) | US6177121B1 (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6410521B1 (en) * | 1998-06-12 | 2002-06-25 | Osteoscreen, Inc. | Nutritional supplements for stimulating bone growth |
US20030194394A1 (en) * | 2002-03-07 | 2003-10-16 | Seong-Tshool Hong | Methods for producing low cholesterol animal products using hypocholesterolemic feed supplements and products therefrom |
US6642202B2 (en) * | 2002-03-12 | 2003-11-04 | Nosan Corporation | Egg having active oxygen eliminating ability and method of producing same |
US20050261354A1 (en) * | 2004-04-29 | 2005-11-24 | John Griffin | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
US20050272770A1 (en) * | 2004-04-29 | 2005-12-08 | John Griffin | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
WO2005115397A2 (en) * | 2004-04-29 | 2005-12-08 | Pharmix Corporation | Compositions and treatments for modulating kinase and/or hmg-coa reductase |
US20050277653A1 (en) * | 2004-04-29 | 2005-12-15 | John Griffin | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
US20050282883A1 (en) * | 2004-04-29 | 2005-12-22 | John Griffin | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
US20050288306A1 (en) * | 2004-04-29 | 2005-12-29 | John Griffin | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
US20060084695A1 (en) * | 2004-04-29 | 2006-04-20 | John Griffin | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
US20060111436A1 (en) * | 2004-11-23 | 2006-05-25 | John Griffin | Compositions and treatments for modulating kinase and/or HMG-CoA reductase |
KR100637762B1 (en) | 2004-07-30 | 2006-10-23 | 주식회사 지니스 | Cholesterol lowering supplements and low cholesterol eggs |
US7533490B2 (en) | 2005-06-30 | 2009-05-19 | Innovated Agricultural Concepts, Llc | Method for creating a verified food source |
US20110217412A1 (en) * | 2004-07-30 | 2011-09-08 | Jinis Biopharmaceuticals Co. | Cholesterol lowering supplement and low cholesterol egg produced by using the same |
US9334266B2 (en) | 2009-09-04 | 2016-05-10 | The University Of Toledo | Catalysts and related processes for producing optically pure beta-lactones from aldehydes and compositions produced thereby |
CN107594139A (en) * | 2017-10-23 | 2018-01-19 | 蚌埠市禹会区天河湖斯祥甲鱼养殖农民专业合作社 | A kind of soft-shelled turtle feed for improving breeding water body and preparation method thereof |
CN108077634A (en) * | 2017-12-08 | 2018-05-29 | 重庆昇顺科技有限公司 | A kind of feed for reducing quail egg fat content |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2742152B1 (en) * | 2011-08-12 | 2017-04-12 | Qiagen GmbH | Method for isolating nucleic acids |
CN103494010B (en) * | 2013-08-27 | 2015-08-05 | 安徽省瑞森生物科技有限责任公司 | A kind of Large-broiler forage and preparation method thereof |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3983140A (en) | 1974-06-07 | 1976-09-28 | Sankyo Company Limited | Physiologically active substances |
US4049495A (en) | 1974-06-07 | 1977-09-20 | Sankyo Company Limited | Physiologically active substances and fermentative process for producing the same |
US4137322A (en) | 1976-11-02 | 1979-01-30 | Sankyo Company Limited | ML-236B carboxylic acid derivatives and their use as antihyperlipemic agents |
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
US4346227A (en) | 1980-06-06 | 1982-08-24 | Sankyo Company, Limited | ML-236B Derivatives and their preparation |
US4432996A (en) | 1980-11-17 | 1984-02-21 | Merck & Co., Inc. | Hypocholesterolemic fermentation products and process of preparation |
US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US4603142A (en) | 1984-06-01 | 1986-07-29 | Wisconsin Alumni Research Foundation | Cholesterol lowering method of use |
US4647576A (en) | 1984-09-24 | 1987-03-03 | Warner-Lambert Company | Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis |
US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US5273995A (en) | 1989-07-21 | 1993-12-28 | Warner-Lambert Company | [R-(R*R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino) carbonyl]- 1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof |
-
1998
- 1998-09-29 US US09/162,522 patent/US6177121B1/en not_active Expired - Fee Related
-
2000
- 2000-12-04 US US09/729,595 patent/US20010006697A1/en not_active Abandoned
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3983140A (en) | 1974-06-07 | 1976-09-28 | Sankyo Company Limited | Physiologically active substances |
US4049495A (en) | 1974-06-07 | 1977-09-20 | Sankyo Company Limited | Physiologically active substances and fermentative process for producing the same |
US4137322A (en) | 1976-11-02 | 1979-01-30 | Sankyo Company Limited | ML-236B carboxylic acid derivatives and their use as antihyperlipemic agents |
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
US4346227A (en) | 1980-06-06 | 1982-08-24 | Sankyo Company, Limited | ML-236B Derivatives and their preparation |
US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US4432996A (en) | 1980-11-17 | 1984-02-21 | Merck & Co., Inc. | Hypocholesterolemic fermentation products and process of preparation |
US4603142A (en) | 1984-06-01 | 1986-07-29 | Wisconsin Alumni Research Foundation | Cholesterol lowering method of use |
US4647576A (en) | 1984-09-24 | 1987-03-03 | Warner-Lambert Company | Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis |
US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US5273995A (en) | 1989-07-21 | 1993-12-28 | Warner-Lambert Company | [R-(R*R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino) carbonyl]- 1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof |
Non-Patent Citations (15)
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6410521B1 (en) * | 1998-06-12 | 2002-06-25 | Osteoscreen, Inc. | Nutritional supplements for stimulating bone growth |
US20030194394A1 (en) * | 2002-03-07 | 2003-10-16 | Seong-Tshool Hong | Methods for producing low cholesterol animal products using hypocholesterolemic feed supplements and products therefrom |
US8715716B2 (en) | 2002-03-07 | 2014-05-06 | Jinis Biopharmaceuticals Co. | Methods for producing low cholesterol animal products using hypocholesterolemic feed supplements and products therefrom |
US6642202B2 (en) * | 2002-03-12 | 2003-11-04 | Nosan Corporation | Egg having active oxygen eliminating ability and method of producing same |
US7163945B2 (en) | 2004-04-29 | 2007-01-16 | Pharmix Corp. | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
US20070004758A1 (en) * | 2004-04-29 | 2007-01-04 | John Griffin | Compositions and treatments for inhibiting kinase and/or hmg-coa reductase |
US20050277653A1 (en) * | 2004-04-29 | 2005-12-15 | John Griffin | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
US20050282883A1 (en) * | 2004-04-29 | 2005-12-22 | John Griffin | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
US20050288306A1 (en) * | 2004-04-29 | 2005-12-29 | John Griffin | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
US20060084695A1 (en) * | 2004-04-29 | 2006-04-20 | John Griffin | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
WO2005115397A2 (en) * | 2004-04-29 | 2005-12-08 | Pharmix Corporation | Compositions and treatments for modulating kinase and/or hmg-coa reductase |
WO2005115397A3 (en) * | 2004-04-29 | 2006-07-13 | Pharmix Corp | Compositions and treatments for modulating kinase and/or hmg-coa reductase |
US20050261354A1 (en) * | 2004-04-29 | 2005-11-24 | John Griffin | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
US20080021054A1 (en) * | 2004-04-29 | 2008-01-24 | John Griffin | Compositions and treatments for inhibiting kinase and/or hmg-coa reductase |
US20050272770A1 (en) * | 2004-04-29 | 2005-12-08 | John Griffin | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
US7183285B2 (en) | 2004-04-29 | 2007-02-27 | Pharmix Corp. | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
US7199126B2 (en) | 2004-04-29 | 2007-04-03 | Pharmix Corporation | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
CN1993122B (en) * | 2004-07-30 | 2011-04-13 | 吉尼思生物制药株式会社 | Cholesterol lowering supplement and low cholesterol egg produced by using the same |
KR100637762B1 (en) | 2004-07-30 | 2006-10-23 | 주식회사 지니스 | Cholesterol lowering supplements and low cholesterol eggs |
US20090181150A1 (en) * | 2004-07-30 | 2009-07-16 | Kim Jeong Hak | Cholesterol lowering supplement and low cholesterol egg produced by using the same |
US20110217412A1 (en) * | 2004-07-30 | 2011-09-08 | Jinis Biopharmaceuticals Co. | Cholesterol lowering supplement and low cholesterol egg produced by using the same |
US20060111436A1 (en) * | 2004-11-23 | 2006-05-25 | John Griffin | Compositions and treatments for modulating kinase and/or HMG-CoA reductase |
US7836631B2 (en) | 2005-06-30 | 2010-11-23 | Innovative Agricultural Concepts, Llc | Method for creating a verified food source |
US20090188163A1 (en) * | 2005-06-30 | 2009-07-30 | Innovative Agriocultural Concepts, Llc | Method For Creating A Verified Food Source |
US7533490B2 (en) | 2005-06-30 | 2009-05-19 | Innovated Agricultural Concepts, Llc | Method for creating a verified food source |
US9334266B2 (en) | 2009-09-04 | 2016-05-10 | The University Of Toledo | Catalysts and related processes for producing optically pure beta-lactones from aldehydes and compositions produced thereby |
CN107594139A (en) * | 2017-10-23 | 2018-01-19 | 蚌埠市禹会区天河湖斯祥甲鱼养殖农民专业合作社 | A kind of soft-shelled turtle feed for improving breeding water body and preparation method thereof |
CN108077634A (en) * | 2017-12-08 | 2018-05-29 | 重庆昇顺科技有限公司 | A kind of feed for reducing quail egg fat content |
Also Published As
Publication number | Publication date |
---|---|
US20010006697A1 (en) | 2001-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6177121B1 (en) | Composition and method for producing low cholesterol eggs | |
Elkin et al. | Select 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors vary in their ability to reduce egg yolk cholesterol levels in laying hens through alteration of hepatic cholesterol biosynthesis and plasma VLDL composition | |
US5360613A (en) | Method of reducing blood levels of total cholesterol and low-density lipoprotein cholesterol | |
Roura et al. | Prevention of immunologic stress contributes to the growth-permitting ability of dietary antibiotics in chicks | |
JP5246833B2 (en) | Adiponectin production enhancer | |
Friedman et al. | Effect of dietary fatty acids on antibody production and fatty acid composition of lymphoid organs in broiler chicks | |
AU761266B2 (en) | Method for reducing the damaging effects of radiation therapy on animal skin and mucosa | |
Elkin | Reducing shell egg cholesterol content. II. Review of approaches utilizing non-nutritive dietary factors or pharmacological agents and an examination of emerging strategies | |
JP2008506773A (en) | Composition comprising protein material and non-oxidizing fatty acid body | |
CN1919199A (en) | Methods for treating psychosis associated with glucocorticoid related dysfunction | |
JP2001505538A (en) | Microbial preparation containing omega-3-fatty acids for use as a prophylactic or therapeutic agent against animal parasitosis | |
JP3873097B2 (en) | Anti-obesity agent and lipid metabolism improving agent | |
JP5246834B2 (en) | Adiponectin production enhancer | |
JP2001031566A (en) | Inhibitory composition for problematic behavior of pet | |
Yin et al. | NO-1886 decreases ectopic lipid deposition and protects pancreatic beta cells in diet-induced diabetic swine | |
Kairalla et al. | Effect of diet supplemented with graded levels of ginger (Zingiber officinale) powder on growth performance, hematological parameters, and serum lipids of broiler chickens. | |
JPH10231495A (en) | Substance having function of preventing growing fat and of decreasing accumulated fan in viscera and its use | |
KR100798217B1 (en) | Use of phytanic acid for the treatment of diabetes | |
Taraz | Garlic powder as blood serum and egg yolk cholesterol lowering agent | |
US20120172425A1 (en) | Red yeast rice extract high in monacolin k content | |
Kuo et al. | Caffeamide 36-13 regulates the antidiabetic and hypolipidemic signs of high-fat-fed mice on glucose transporter 4, AMPK phosphorylation, and regulated hepatic glucose production | |
JP2001240544A (en) | Anti-obesity medicine and lipid metabolism-improving medicine | |
US5985845A (en) | Methods for reducing mortality rates in poultry | |
JPH0912466A (en) | Lipid absorption-inhibiting and extrusion-stimulating agent and high fat food | |
JP2023081768A (en) | Therapeutic agent for fatty liver, pharmaceutical composition, treatment method, and screening method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: PURDUE RESEARCH FOUNDATION, INDIANA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ELKIN, ROBERT G.;YAN, ZHIHONG;REEL/FRAME:009494/0380 Effective date: 19980925 |
|
CC | Certificate of correction | ||
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20050123 |